text:
Patent US5023252 - Transdermal and trans-membrane delivery of drugs - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe rate of absorption of drugs across skin and other body membranes such as mucous membranes and the blood brain barrier is enhanced by adding to the drug composition a compound which enhances the rate. This compound may be macrocyclic ester, diester, amide, diamide, amidine, diamidine, thioester, dithioester,...http://www.google.com/patents/US5023252?utm_source=gb-gplus-sharePatent US5023252 - Transdermal and trans-membrane delivery of drugsAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS5023252 APublication typeGrantApplication numberUS 07/449,117Publication dateJun 11, 1991Filing dateDec 8, 1989Priority dateDec 4, 1985Fee statusPaidPublication number07449117, 449117, US 5023252 A, US 5023252A, US-A-5023252, US5023252 A, US5023252AInventorsDean HseihOriginal AssigneeConrex Pharmaceutical CorporationExport CitationBiBTeX, EndNote, RefManPatent Citations (12), Non-Patent Citations (2), Referenced by (749), Classifications (15), Legal Events (13) External Links: USPTO, USPTO Assignment, EspacenetTransdermal and trans-membrane delivery of drugs
TABLE 1______________________________________Flux× 103 dpm/   Total Amount*Adjuvant   cm2 /hr              Ratio %  dpm (× 103)                                Ratio %______________________________________Control 0.16       100      1        100I       0.70       437      3.5      350II      1.07       669      4.8      480III     0.25       156      1.5      150IV      0.25       156      1.7      170______________________________________ *Total amount of triamincinolone acetonide which penetrated at the end of 10 hours.
TABLE 5______________________________________Comparison of permeation rat of hydrocortisone throughhairless mouse skin by different cyclic ketones          Permeation Rate                       EnhancementChemical(s)    (ug/cm*cm/hr)                       factor (%)______________________________________None or control          5.25 × 10-5                       100cyclononanone  5.96 × 10-5                       113cyclodecanone  3.79 × 10-5                        72cycloundecanone          3.91 × 10-5                        74cyclododecanone          1.21 × 10-4                       230cyclotridecanone          2.75 × 10-4                       524cyclopentadecanone          3.10 × 10-4                       590cyclopentadecanolide          8.94 × 10-4                       1703______________________________________ 1. The concentration of chemical used in the donor compartment was 2%. 2. Permeation rates were calculated from the slope of permeation profile. 3. The enhancement factor was calculated based upon the control group (without chemical) as 100.
TABLE 6______________________________________Concentration of Adjuvant           Flux (dpm/cm2 /hr)                         Ratio (%)______________________________________10               7.4 × 103                         46255                4.1 × 103                         25633                3.7 × 103                         23102                3.7 × 103                         23101               0.31 × 103                          2000.5             0.31 × 103                          1000 (Control)     0.16 × 103                          100______________________________________ Studies with Oxacyclohexadecan2-one or cyclopentadeconolide
TABLE 7______________________________________Triamcinolone acetonide penetration parameters with andwithout cyclopentadecanolide   Lag       KP       DEnhancer   time (hr) (cm/hr)  (cm2 /hr)                                Km______________________________________None    --        --       --        --cyclopenta-   6.03      3.88     4.42 × 10-7                                3.51 × 104decanolide(2%)______________________________________
TABLE 9______________________________________Concentration  Flux%              (dpm/cm2 /hr)                      Ratio (%)______________________________________10              0.3 × 103                      30005               0.3 × 103                      30003               0.22 × 103                      22002               0.15 × 103                      15001               0.10 × 103                      10000.5            0.013 × 103                       1300% (with       0.025 × 103                       250ethanol)0% (no         0.010 × 103                       100ethanol)______________________________________
TABLE 10______________________________________Adjuvant    Flux (dpm/cm2 /hr)                     Ratio (%)______________________________________Control     1.88 × 103                     1000.4% I      8.13 × 103                     4322% III      3.63 × 103                     193______________________________________
TABLE 11__________________________________________________________________________Effect of Skin Penetration Enhancers on Tape Propertiesof 355 Pressure Sensitive AdhesiveSkin   Loading       Initial Tape PropertiesaEnhancer  Wt % Tack (g/cm2)               Peel (g/cm)                      Adhesion (g/cm)__________________________________________________________________________Control  0    92.0    1 +/- 0.2                      290.0CIB-01 1    358.0   1.8    342.0(cyclopenta  5    624.0   7.3    256.3decanone)  10   780.7   9.1    193.7Ethanolb  1    119.7   1.1    269.3  5    239.0   1.4    263.0  10   314.3   1.1    305.5Isopropyl  1    407.3   3.5    506.6Palmitate  5    864.0   9.1    172.6*  10   284.0   3.9    58.7**Azone ®  1    357.6   1.4    290.4  5    212.7   2.5    322.7**  10   113.3   2.5    389.9**__________________________________________________________________________ 1 Samples were handcoated with a No. 8 coating bar. Severe compromis of tape properties (*), cohesive failure (**). b Ethanol was very volatile and vaporized out during preparations. The final concentration of ethanol remaining in the patch was not able to be determined.
TABLE 12__________________________________________________________________________Effect of Skin Penetration Enhancers on Tape Propertiesof X7-2920 Amine Resistant Pressure Sensitive AdhesiveSkin   Loading       Initial Tape PropertiesaEnhancer  Wt % Tack (g/cm2)               Peel (g/cm)                      Adhesion (g/cm)__________________________________________________________________________Control  0    612.7   11.8   1170.0CIB-01 1    573.3   8.4    831.0(cyclopenta-  5    598.0   11.6   2124.0decanone)  10   915.3   15.5   2137.0Ethanolb  1    246.3   3.5    --  5    297.0   4.2    967.6  10   288.3   5.6    960.1Isopropyl  1    385.3   6.3    204.5Palmitate  5    712.0   10.9   204.5  10   524.7   14.1   290.7**Azone ®  1    312.0   1.8    1509.0  5    703.0   16.9   1238.0**  10   714.3   22.9   1424.0**__________________________________________________________________________ a Samples were handcoated with a No. 8 coating bar. Severe compromis of tape properties, cohesive failure (**). b Ethanol was very volatile and vaporized out during fabrication. Th final concentration of ethanol remaining in the patch was not able to be determined.
TABLE 13__________________________________________________________________________Effect of Skin Penetration Enhancers on Tape Properties ofX7-2920 Amine Resistant Pressure Sensitive AdhesiveSkin   Loading       Initial Tape PropertiesaEnhancer  Wt % Tack (g/cm2)               Peel (g/cm)                      Adhesion (g/cm)__________________________________________________________________________Control  0    115.0   0.7 +/- 0.9                      720 +/- 38CIB-01 1    105.0   0.2 +/- 0.2                      681 +/- 16(cylclopenta-  5    403.0   7.0 +/- 1.4                      623 +/- 29decanone)  10   857.0   0.7 +/- 0.4                      698 +/- 12Ethanolb  1    84.0    1.0 +/- 0.4                      697 +/- 10  5    72.0    1.4 +/- 0.7                      736 +/- 31  10   60.0    18.9 +/- 1.1                      477 +/- 50Isopropyl  1    171.0   1.8 +/- 0.4                      639 +/- 38Palmitate  5    845.0   18.6 +/- 1.4                      400 +/- 71  10   758.0   17.2 +/- 2.8                       445 +/- 91**Azone ®  1    758.0   1.4 +/- 0.4                      716 +/- 46  5    535.0   7.0 +/- 1.4                      723 +/- 57  10   706.0   22.9 +/- 4.2                       320 +/- 42**__________________________________________________________________________ a Machinecoated samples. Severe compromise of tape properties, cohesive failure (**). b Ethanol was very volatile and vaporized out during fabrication. Th final concentration of ethanol remaining in the patch can not be determined.
TABLE 14__________________________________________________________________________Compatibility of Skin Penetration Enhancers with DOW CORNING ®355 Medical Grade Pressure Sensitive Silicone Adhesive      Initial Tape Properties, Mean +/- SDSkin  Loading      Tack    Peel       AdhesionEnhancer Wt % (g/cm2)           %-- a              (g/cm) %-- a                         (g/cm)  %-- a__________________________________________________________________________Control 0    187.0           -- 1.4 +/- 0.0                     --  466.1 +/- 17.9                                 --CIB-01b 1    339.0           +81              2.8 +/- 0.0                     +100                         458.1 +/- 17.9                                 -2Azone 1    114.7           -38              2.8 +/- 0.4                     +100                         502.4 +/- 66.1                                 +8Ethanol 1    134.3           -28              1.4 +/- 1.0                     +0  554.0 +/- 23.6                                  +18Isopropyl 1    295.3           +58              7.4 +/- 0.7                     +21 486.2 +/- 27.8                                 +4MyristateIsopropyl 1    229.3           +22              6.3 +/- 0.7                     +350                         536.8 +/- 32.0                                  +15PalmitateEucalyptol 1    158.7           -15              1.4 +/- 1.1                     +0  465.4 +/- 23.6                                 -2__________________________________________________________________________ a Percent change from control values for machinecoated laminates 1 mil thick. b CIB01 is cyclopentadecanone.
TABLE 15__________________________________________________________________________Compatibility of Skin Penetration Enhancers with DOW CORNING ®355 Medical Grade Pressure Sensitive Silicone Adhesive      Tape Properties, Mean +/- SDSkin  Loading      After Two Weeks AgingEnhancer Wt % Tack          %-- a             Peel   %-- a                       Adhesion                               %-- a__________________________________________________________________________Control 0    53.0          -71             0.7 +/- 0.0                    -50                       444.0 +/- 4.9                               -5CIB-01b 1    103.0          -70             1.4 +/- 0.3                    +50                       515.7 +/- 32.6                               +13Azone 1    90.0          -22             1.8 +/- 0.4                    +36                       483.0 +/- 19.3                               -4Ethanol 1    48.7*          -63             2.1 +/- 0.4                    +50                       525.6 +/- 3.2                               -5Isopropyl 1    185.7          -37             3.9 +/- 0.7                    -47                       428.5 +/- 78.4                               -12MyristateIsopropyl 1    167.3          -27             8.1 +/--                    +30                       414.1 +/- 60.8                               +23PalmitateEucalyptol 1    41.0*          -74             0.4 +/- 0.7                    -71                       416.6 +/- 95.9                               -10__________________________________________________________________________ a Percent change in the tape properties from initial for 1 mil thick machinecoated laminates. Severe compromise in tape properties. (*) b CIC01 is cyclopentadecanone.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3474176 *Dec 6, 1965Oct 21, 1969Int Flavors & Fragrances IncRepelling animals with ketoneUS3921636 *Apr 22, 1974Nov 25, 1975Alza CorpNovel drug delivery deviceUS3964482 *May 17, 1971Jun 22, 1976Alza CorporationDrug delivery deviceUS3996934 *Aug 9, 1971Dec 14, 1976Alza CorporationMedical bandageUS4405616 *May 20, 1982Sep 20, 1983Nelson Research & Development CompanyPenetration enhancers for transdermal drug delivery of systemic agentsUS4415563 *Dec 7, 1981Nov 15, 1983Nelson Research & Development CompanyVehicle composition containing 1-substituted azacyclononan-2-onesUS4557934 *Jun 21, 1983Dec 10, 1985The Procter & Gamble CompanyPenetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-oneUS4590170 *Jul 8, 1981May 20, 1986Fuji Photo Film Co., Ltd.Process for preparing microcapsule reagents for immunological responseUS4710497 *May 31, 1985Dec 1, 1987Nitto Electric Industrial Co., Ltd.Method for percutaneously administering physiologically active agentsEP0129284A2 *Jun 12, 1984Dec 27, 1984THE PROCTER & GAMBLE COMPANYImproved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-oneGB2142237A * Title not availableWO1986002583A1 *Oct 17, 1985May 9, 1986Amepa Angewandte Messtechnik Und ProzessautomatisiProcess and device for detecting slag* Cited by examinerNon-Patent CitationsReference1Jones, "Transdermal and Related Drug Delivery Systems", Noyes Data Corp. (U.S.A.), pp. 109-137, (1984).2 *Jones, Transdermal and Related Drug Delivery Systems , Noyes Data Corp. (U.S.A.), pp. 109 137, (1984).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5731303 *Dec 22, 1994Mar 24, 1998Conrex Pharmaceutical CorporationTransdermal and trans-membrane delivery compositionsUS5739118 *Apr 1, 1994Apr 14, 1998Apollon, Inc.Compositions and methods for delivery of genetic materialUS5783434 *Jun 6, 1995Jul 21, 1998Tung; Jay S.Cathepsin and methods and compositions for inhibition thereofUS5827819 *Oct 25, 1996Oct 27, 1998Oregon Health Sciences UniversityCovalent polar lipid conjugates with neurologically active compounds for targetingUS5849711 *Jun 6, 1995Dec 15, 1998Athena Neurosciences, Inc.Cathepsin and methods and compositions for inhibition thereofUS5858398 *Nov 3, 1994Jan 12, 1999Isomed Inc.Microparticular pharmaceutical compositionsUS5858982 *May 2, 1997Jan 12, 1999Athena Neurosciences, Inc.Cathepsin and methods and compositions for inhibition thereofUS5962428 *Mar 30, 1995Oct 5, 1999Apollon, Inc.Compositions and methods for delivery of genetic materialUS6024977 *Sep 3, 1997Feb 15, 2000Oregon Health Sciences UniversityCovalent polar lipid conjugates with neurologically active compounds for targetingUS6057372 *May 21, 1997May 2, 2000Soda Aromatic Co., Ltd.Antibacterial agents and cosmetics and clothing containing the sameUS6121000 *Feb 11, 1999Sep 19, 2000Genesense Technologies, Inc.Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseUS6197755May 27, 1999Mar 6, 2001The Trustees Of The University Of PennsylvaniaCompositions and methods for delivery of genetic materialUS6313152Sep 7, 1999Nov 6, 2001Athena Neurosciences, Inc.N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compoundsUS6333351May 3, 1999Dec 25, 2001Athena Neurosciences, Inc.N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compoundsUS6337423Apr 2, 1999Jan 8, 2002Advanced Medicine, Inc.Local anesthetic compounds and usesUS6339060May 16, 2000Jan 15, 2002Oregon Health & Science UniversityConjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targetingUS6348450May 3, 2000Feb 19, 2002The Uab Research FoundationNoninvasive genetic immunization, expression products therefrom and uses thereofUS6380356Dec 7, 1999Apr 30, 2002Advanced Medicine, Inc.Multivalent polymyxin antibioticsUS6417169Apr 22, 1999Jul 9, 2002Genesense Technologies Inc.Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growthUS6420354Dec 8, 1999Jul 16, 2002Advanced Medicine, Inc.Sodium channel drugs and usesUS6436437Feb 15, 2000Aug 20, 2002Oregon Health And Science UniversityCovalent polar lipid conjugates with neurologically active compounds for targetingUS6462034Oct 1, 1999Oct 8, 2002Theravance, Inc.Local anesthetic compounds and usesUS6479498Nov 9, 2001Nov 12, 2002Theravance, Inc.Sodium channel drugs and usesUS6495124 *Feb 14, 2000Dec 17, 2002Macrochem CorporationAntifungal nail lacquer and method using sameUS6495681Oct 17, 2000Dec 17, 2002Theravance Inc.Local anesthetic compounds and usesUS6521755May 26, 2000Feb 18, 2003Eli Lilly And CompanyProcess for preparing 10,11-methanobenzosuberane derivativesUS6528305Aug 2, 2001Mar 4, 2003Oncolytics Biotech, Inc.Method of producing infectious reovirusUS6528511Feb 15, 2001Mar 4, 2003Cv Therapeutics, Inc.Partial fatty acid oxidation inhibitors in the treatment of congestive heart failureUS6548548Dec 6, 2001Apr 15, 2003Cv Therapeutics, Inc.ABCA-1 elevating compoundsUS6565831Aug 10, 2000May 20, 2003Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS6566509Jun 8, 1999May 20, 2003Theravance, Inc.Multivalent macrolide antibioticsUS6566514Jan 29, 1999May 20, 2003Genesense Technologies Inc.Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growthUS6576791Apr 2, 1999Jun 10, 2003Theravance, Inc.Local anesthetic compounds and usesUS6579256 *Oct 4, 1999Jun 17, 2003Photogenesis, Inc.Instrument for subretinal implantationUS6585963Apr 10, 2001Jul 1, 2003Watson Pharmaceuticals, Inc.Nail compositions and methods of administering sameUS6593305Feb 11, 1999Jul 15, 2003Genesense Technologies Inc.Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseUS6638924Aug 28, 2001Oct 28, 2003Pharmacyclics, Inc.Metallotexaphyrin derivativesUS6642261Oct 31, 2001Nov 4, 2003Athena Neurosciences, Inc.N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compoundsUS6677342Aug 27, 2002Jan 13, 2004Cv Therapeutics, Inc.Partial fatty acid oxidation inhibitors in the treatment of congestive heart failureUS6703232Jan 8, 2003Mar 9, 2004Oncolytics Biotech Inc.Method of producing infectious reovirusUS6706693Aug 13, 1998Mar 16, 2004The Uab Research FoundationVaccination by topical application of genetic vectorsUS6713650Dec 5, 2001Mar 30, 2004Prabha N. IbrahimABCA-1 elevating compoundsUS6716823Mar 23, 2000Apr 6, 2004The Uab Research FoundationNoninvasive genetic immunization, expression products therefrom, and uses thereofUS6767918Dec 9, 2002Jul 27, 2004Athena Neurosciences, Inc.N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compoundsUS6794376Sep 12, 2001Sep 21, 2004William Beaumont HospitalMethods and compositions for enhancing diffusion of therapeutic agents through tissueUS6797276Feb 25, 1999Sep 28, 2004The United States Of America As Represented By The Secretary Of The ArmyUse of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune responseUS6858582Jan 15, 2002Feb 22, 2005Oregon Health And Sciences UniversityComposition containing porous microparticle impregnated with biologically-active compound for treatment of infectionUS6875784Oct 2, 2003Apr 5, 2005Pharmacia & Upjohn CompanyAntimibicrobial [3.1.0.] bicyclic oxazolidinone derivativesUS6897305Dec 8, 1999May 24, 2005Theravance, Inc.Calcium channel drugs and usesUS6900203Jul 8, 2002May 31, 2005Polium Technologies, Inc.Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising themUS6919327Nov 16, 2001Jul 19, 2005Pharmacyclics, Inc.Texaphyrin coordination compounds and uses thereofUS6919339Dec 4, 2001Jul 19, 2005Cv Theapeutics, Inc.ABCA-1 elevating compoundsUS7008949May 27, 2003Mar 7, 2006Elan Pharmaceuticals, Inc.Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsUS7014847Mar 28, 2003Mar 21, 2006Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS7026328May 27, 2003Apr 11, 2006Elan Pharmaceuticals, Inc.Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsUS7034055Jun 30, 2000Apr 25, 2006Prescient Neuropharma Inc.2-aminoindane analogsUS7037499Mar 12, 1999May 2, 2006The United States Of America As Represented By The Secretary Of The ArmyAdjuvant for transcutaneous immunizationUS7045543Nov 5, 2001May 16, 2006Enzrel Inc.Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sitesUS7048934Aug 30, 2002May 23, 2006Stem Cell Therapeutics Inc.Combined regulation of neural cell productionUS7049127Dec 11, 2003May 23, 2006Oncolytics Biotech Inc.Method of producing infectious reovirusUS7070799Mar 30, 2000Jul 4, 2006Generex Pharmaceuticals, Inc.Method for administering insulin to the buccal regionUS7101909Jun 25, 2004Sep 5, 2006Theravance, Inc.Calcium channel drugs and usesUS7112561Dec 2, 2004Sep 26, 2006Bentley Pharmaceuticals, Inc.Pharmaceutical compositions and methods for insulin treatmentUS7135477May 27, 2003Nov 14, 2006Elan Pharmaceuticals, Inc.Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrinsUS7163678Nov 6, 2003Jan 16, 2007Oncolytics Biotech Inc.Reovirus for the treatment of ral-mediated cellular proliferative disordersUS7244703Mar 5, 2004Jul 17, 2007Bentley Pharmaceuticals, Inc.Pharmaceutical compositions and methods for peptide treatmentUS7244764Jun 18, 2004Jul 17, 2007Neurochem (International) LimitedMethods and compositions for treating amyloid-related diseasesUS7320968 *Apr 21, 2003Jan 22, 2008Bentley Pharmaceuticals, Inc.Pharmaceutical compositionUS7335663May 27, 2003Feb 26, 2008Elan Pharmaceuticals, Inc.Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrinsUS7358068Sep 12, 2003Apr 15, 2008Replicor, Inc.Antiviral oligonucleotidesUS7364758Aug 31, 2004Apr 29, 2008Shih-Lan HsuPharmaceutical use of Graptopetalum and related plantsUS7368115Jul 31, 2003May 6, 2008Stem Cell Therapeutics Inc.Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)US7371875Mar 11, 2005May 13, 2008Miikana Therapeutics, Inc.Cytotoxic agents and methods of useUS7374752Aug 11, 2004May 20, 2008Oncolytics Biotech Inc.Reovirus for the treatment of cellular proliferative disordersUS7378097Mar 3, 2004May 27, 2008The United States Of America As Represented By The Secretary Of The ArmyUse of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvantUS7393830Aug 30, 2002Jul 1, 2008Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbersUS7405205May 29, 2003Jul 29, 2008Lorus Therapeutics Inc.Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseUS7414076Jun 18, 2004Aug 19, 2008Neurochem (International) LimitedMethods and compositions for treating amyloid-related diseasesUS7423010Feb 22, 2005Sep 9, 2008Oregon Health & Science UniversityNonporous microparticle-prodrug conjugates for treatment of infectionUS7423045Jun 28, 2006Sep 9, 2008Cv Therapeutics, Inc.ABCA1 elevating compoundsUS7429485Mar 27, 2006Sep 30, 2008Oncolytics Biotech Inc.Method of producing infectious reovirusUS7432276Dec 27, 2006Oct 7, 2008Cv Therapeutics, Inc.ABCA1 elevating compoundsUS7432307Nov 4, 2005Oct 7, 2008Sirion Therapeutics, Inc.Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formationUS7432371Feb 7, 2003Oct 7, 2008Covalent Partners, LlcNanofilm and membrane compositionsUS7449454Sep 10, 2003Nov 11, 2008Pharmacyclics, Inc.Metallotexaphyrin derivativesUS7452723Oct 21, 2005Nov 18, 2008Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS7488720Oct 11, 2006Feb 10, 2009Cv Therapeutics, Inc.A1 adenosine receptor agonistsUS7511052Sep 28, 2006Mar 31, 2009Elan Pharmaceuticals, Inc.Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4US7524510Feb 23, 2006Apr 28, 2009The Uab Research FoundationAlkyl-glycoside enhanced vaccinationUS7527802Feb 13, 2002May 5, 2009The United States Of America As Represented By The Secretary Of The ArmyVaccine for transcutaneous immunizationUS7534765Sep 27, 2006May 19, 2009Stem Cell Therapeutics Corp.Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactinUS7579466Feb 26, 2007Aug 25, 2009Elan Pharmaceuticals, Inc.Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4US7582289May 30, 2007Sep 1, 2009Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS7598269May 30, 2007Oct 6, 2009Bellus Health (International) LimitedMethods and compositions for treating amyloid-related diseasesUS7604993Jan 30, 2006Oct 20, 2009Stem Cell Therapeutics Inc.Combined regulation of neural cell productionUS7608605Jan 20, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7608606Jan 20, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7608607Jan 21, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7608608Jan 23, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7608609Jan 23, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7608610Feb 2, 2009Oct 27, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7625881Jun 14, 2006Dec 1, 2009Gilead Palo Alto, Inc.Prodrugs of A2B adenosine receptor antagonistsUS7651996Aug 24, 2006Jan 26, 2010Cpex Pharmaceuticals, Inc.Pharmaceutical compositions and methods for insulin treatmentUS7655638Nov 15, 2006Feb 2, 2010Gilead Palo Alto, Inc.Partial and full agonists of A1 adenosine receptorsUS7662819Oct 5, 2007Feb 16, 2010Gilead Palo Alto, Inc.Pteridinone derivatives for use as stearoyl CoA desaturase inhibitorsUS7670849May 1, 2006Mar 2, 2010Henkin Robert IMethod for diagnosing insulin resistance from nasal secretionsUS7687453 *Mar 3, 2003Mar 30, 2010Generex Pharmaceuticals IncorporatedMethod for administering insulin to the buccal regionUS7696181Aug 24, 2006Apr 13, 2010Cv Therapeutics, Inc.Partial and full agonists of A1 adenosine receptorsUS7708987May 30, 2007May 4, 2010Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS7713946Dec 18, 2006May 11, 2010Cv Therapeutics, Inc.Partial and full agonists A1 adenosine receptorsUS7727996Sep 28, 2006Jun 1, 2010Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4US7731951Nov 7, 2006Jun 8, 2010Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS7732453Oct 5, 2007Jun 8, 2010Gilead Palo Alto, Inc.Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA desaturase inhibitorsUS7741328Oct 16, 2006Jun 22, 2010Elan Pharmaceuticals, Inc.Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4US7745460Oct 29, 2007Jun 29, 2010Sarcode CorporationModulators of cellular adhesionUS7763252May 30, 2007Jul 27, 2010Oncolytics Biotech Inc.Methods for the treatment of cellular proliferative disordersUS7763632Jan 12, 2009Jul 27, 2010Elan Pharmaceuticals, Inc.Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4US7790743Nov 1, 2007Sep 7, 2010Sarcode CorporationModulators of cellular adhesionUS7799329May 30, 2007Sep 21, 2010Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS7815914Mar 31, 2006Oct 19, 2010Oncolytics Biotech Inc.Methods for the treatment of cellular proliferative disordersUS7820646Jan 3, 2008Oct 26, 2010Novartis Vaccines And Diagnostics, Inc.Cyclized derivatives as Eg-5 inhibitorsUS7820687Jul 17, 2009Oct 26, 2010Elan Pharmaceuticals, Inc.Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4US7846898Feb 14, 2005Dec 7, 2010Stem Cell Therapeutics Corp.Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesisUS7884072Mar 19, 2008Feb 8, 2011Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbersUS7884120Aug 19, 2003Feb 8, 2011Lorus Therapeutics Inc.2,4,5-trisubstituted imidazoles and their use as anti-microbial agentsUS7893066Apr 9, 2008Feb 22, 2011Gilead Palo Alto, Inc.Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitorsUS7901921Oct 20, 2005Mar 8, 2011Oncolytics Biotech Inc.Viral purification methodsUS7902240Nov 8, 2007Mar 8, 2011Novartis AgSubstituted pyrazole and triazole compounds as KSP inhibitorsUS7928122Aug 6, 2009Apr 19, 2011Sarcode CorporationModulators of cellular adhesionUS7935690 *Oct 30, 2007May 3, 2011Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS7939509Mar 15, 2010May 10, 2011Gilead Sciences, Inc.Partial and full agonists of A1 adenosine receptorsUS7964186May 30, 2007Jun 21, 2011Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS7964563Apr 7, 2009Jun 21, 2011Stem Cell Therapeutics Corp.Oligodendrocyte precursor cell proliferation regulated by prolactinUS7968547Dec 14, 2009Jun 28, 2011Elan Pharmaceuticals, Inc.Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4US7973044Dec 22, 2009Jul 5, 2011Elan Pharmaceuticals, Inc.Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4US7976847Jan 13, 2005Jul 12, 2011Vasogenix Pharmaceuticals, Inc.Controlled release CGRP delivery composition for cardiovascular and renal indicationsUS7989419Jun 8, 2007Aug 2, 2011Cpex Pharmaceuticals, Inc.Insulin compositionUS7989626Feb 4, 2011Aug 2, 2011SAR code CorporationModulators of cellular adhesionUS8007805Aug 5, 2004Aug 30, 2011Paladin Labs, Inc.Chimeric antigens for breaking host tolerance to foreign antigensUS8008269Feb 28, 2008Aug 30, 2011Replicor Inc.Antiviral oligonucleotidesUS8008270Apr 9, 2008Aug 30, 2011Replicor Inc.Antiviral oligonucleotides targeting viral familiesUS8025873Aug 5, 2004Sep 27, 2011Paladin Labs, Inc.Chimeric antigens for eliciting an immune responseUS8029803Feb 13, 2003Oct 4, 2011Paladin Labs, Inc.Chimeric antigens for eliciting an immune responseUS8044100Dec 21, 2005Oct 25, 2011Bellus Health Inc.Methods and compositions for treating amyloid-related diseasesUS8048874Jul 18, 2006Nov 1, 2011Azevan Pharmaceuticals, Inc.Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonistsUS8063029 *Oct 31, 2007Nov 22, 2011Fcb I LlcPharmaceutical compositionUS8066985Nov 25, 2008Nov 29, 2011Oncolytics Biotech Inc.Reovirus for the treatment of cellular proliferative disordersUS8067385Jul 10, 2008Nov 29, 2011Replicor, Inc.Antiviral oligonucleotides targeting HBVUS8071075Oct 5, 2007Dec 6, 2011Acrux Dds Pty Ltd.Dermal penetration enhancers and drug delivery systems involving the sameUS8071087Jul 22, 2010Dec 6, 2011Oncolytics Biotech Inc.Reovirus for the treatment of cellular proliferative disordersUS8071617Feb 4, 2011Dec 6, 2011Sarcode Bioscience Inc.Modulators of cellular adhesionUS8080241Apr 16, 2010Dec 20, 2011Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS8080562Apr 15, 2009Dec 20, 2011Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS8084047Jul 23, 2009Dec 27, 2011Sarcode Bioscience Inc.Compositions and methods for treatment of eye disordersUS8088792Apr 3, 2009Jan 3, 2012Gilead Sciences, Inc.Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitorsUS8129358Nov 8, 2007Mar 6, 2012Novartis AgSubstituted pyrazole and triazole compounds as KSP inhibitorsUS8143220Mar 16, 2007Mar 27, 2012Stem Cell Therapeutics Corp.Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disordersUS8143249Jan 21, 2011Mar 27, 2012Gilead Sciences, Inc.Prodrugs of A2B adenosine receptor antagonistsUS8148376Apr 26, 2010Apr 3, 2012Gilead Sciences, Inc.3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitorsUS8158642Oct 15, 2009Apr 17, 2012Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4US8168655May 17, 2006May 1, 2012Sarcode Bioscience Inc.Compositions and methods for treatment of eye disordersUS8178518 *Oct 31, 2007May 15, 2012Fcb I LlcPharmaceutical compositionUS8217002Oct 29, 2010Jul 10, 2012Stem Cell Therapeutics Corp.Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesisUS8217020Nov 19, 2010Jul 10, 2012The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for reducing viral genome amounts in a target cellUS8222212Dec 29, 2010Jul 17, 2012Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbersUS8236288Jan 6, 2012Aug 7, 2012Skinmedica, Inc.Melanin modification compositions and methods of useUS8268887Oct 8, 2009Sep 18, 2012Feng XuDrug conjugates and methods of use thereofUS8293489Jan 31, 2008Oct 23, 2012Henkin Robert IMethods for detection of biological substancesUS8314104Apr 7, 2010Nov 20, 2012Gilead Sciences, Inc.Method of treating diabetesUS8314152Jun 10, 2005Nov 20, 2012Acucela, Inc.Methods and compositions for treating ophthalmic conditions with retinyl derivativesUS8333974Mar 16, 2007Dec 18, 2012Stem Cell Therapeutics Corp.Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agentsUS8361272Jun 27, 2007Jan 29, 2013Ferring B.V.Polyurethane elastomersUS8361273Sep 6, 2012Jan 29, 2013Ferring B.V.Polyurethane elastomersUS8367688Apr 13, 2010Feb 5, 2013Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4US8367701Nov 4, 2011Feb 5, 2013Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS8367836Apr 27, 2010Feb 5, 2013Elan Pharmaceuticals, Inc.Pyridinone antagonists of alpha-4 integrinsUS8378105Oct 21, 2010Feb 19, 2013Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS8394815Dec 22, 2010Mar 12, 2013Lorus Therapeutics Inc.2,4,5-trisubstituted imidazoles and their use as anti-microbial agentsUS8399473Oct 2, 2007Mar 19, 2013Merck, Sharp & Dohme, Corp.Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's diseaseUS8410168Apr 21, 2010Apr 2, 2013Acucela, Inc.Methods and compositions for treating ophthalmic conditions with retinyl derivativesUS8410263Nov 3, 2009Apr 2, 2013Pharmacyclics, Inc.High-purity texaphyrin metal complexesUS8426400Oct 31, 2011Apr 23, 2013Azevan Pharmaceuticals, Inc.β-lactamyl phenylalanine, cysteine, and serine vasopressin antagonistsUS8435949Jun 11, 2012May 7, 2013Stem Cell Therapeutics Corp.Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesisUS8460707Mar 26, 2012Jun 11, 2013Ferring B.V.Stabilised prostaglandin compositionUS8465745Aug 15, 2011Jun 18, 2013Akshaya Bio Inc.Chimeric antigens for eliciting an immune responseUS8466136Jul 11, 2011Jun 18, 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8466137Jul 11, 2011Jun 18, 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8466138Oct 5, 2011Jun 18, 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8470312May 27, 2009Jun 25, 2013Oncolytics Biotech, Inc.Abrogating proinflammatory cytokine production during oncolytic reovirus therapyUS8470777May 6, 2011Jun 25, 2013Stem Cell Therapeutics Corp.Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactinUS8481043Jun 4, 2010Jul 9, 2013Cpex Pharmaceuticals, Inc.Nasal immunizationUS8486925Oct 5, 2011Jul 16, 2013Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8491886Nov 16, 2011Jul 23, 2013Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS8491934Jul 28, 2005Jul 23, 2013Ferring B.V.Stabilised prostaglandin compositionUS8506934Dec 29, 2009Aug 13, 2013Robert I. HenkinMethods for detection of biological substancesUS8513188Sep 27, 2007Aug 20, 2013Paolo BottiFormulations comprising cyclic compoundsUS8524254Oct 15, 2007Sep 3, 2013Ferring B.V.Bioresorbable polymersUS8557281Jul 13, 2010Oct 15, 2013Ferring B.V.Water-swellable polymersUS8580490Jun 6, 2011Nov 12, 2013Colorado State University Research FoundationMarkers for screening anti-mycobacterial treatment efficacyUS8580801Jul 23, 2009Nov 12, 2013Robert I. HenkinPhosphodiesterase inhibitor treatmentUS8586732Jun 29, 2012Nov 19, 2013Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS8592450Feb 16, 2012Nov 26, 2013Sarcode Bioscience Inc.Compositions and methods for treatment of eye disordersUS8628798Aug 10, 2012Jan 14, 2014Ferring B.V.Water-swellable polymersUS8642801Nov 5, 2009Feb 4, 2014Bhi Limited PartnershipMethods and compositions for treating amyloid-related diseasesUS8663938Sep 14, 2012Mar 4, 2014Robert I. HenkinMethods for detection of biological substancesUS8697863Mar 7, 2013Apr 15, 2014Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS8697876Mar 31, 2011Apr 15, 2014Colucid Pharmaceuticals, Inc.Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonistsUS8703759Jun 30, 2011Apr 22, 2014Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS8709443Nov 2, 2011Apr 29, 2014Oncolytics Biotech Inc.Reovirus for the treatment of cellular proliferative disordersUS8709482May 31, 2013Apr 29, 2014Ferring B.V.Stabilised prostaglandin compositionUS8716319Feb 9, 2010May 6, 2014Gilead Sciences, Inc.Substituted heterocyclic compoundsUS8729057Mar 14, 2013May 20, 2014Unimed Pharmaeuticals, LLCTestosterone gel and method of useUS8741881Mar 14, 2013Jun 3, 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8748459Feb 1, 2012Jun 10, 2014Eli Lilly And CompanyPyridinoylpiperidines as 5-HT1F agonistsUS8754070Mar 14, 2013Jun 17, 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8758776Jan 21, 2011Jun 24, 2014Sarcode Bioscience Inc.Compositions and methods for treatmentUS8759312Jun 21, 2012Jun 24, 2014The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for reducing viral genome amounts in a target cellUS8759329Mar 14, 2013Jun 24, 2014Unimed Pharmaceuticals, LlcTestosterone gel and method of useUS8771715Jan 21, 2011Jul 8, 2014Sarcode Bioscience Inc.Compositions and methods for treatmentUS8778315Feb 26, 2013Jul 15, 2014Allergan, Inc.Melanin modification compositions and methods of useUS8785426Feb 11, 2014Jul 22, 2014Upsher-Smith Laboratories, Inc.Testosterone gel compositions and related methodsUS8795978Jun 20, 2008Aug 5, 2014The Uab Research FoundationModulating latency and reactivation of Mycobacterium tuberculosisUS8809349Jan 10, 2012Aug 19, 2014Infinity Pharmaceuticals, Inc.Processes for preparing isoquinolinones and solid forms of isoquinolinonesUS8822473May 31, 2007Sep 2, 2014Gilead Sciences, Inc.Method of treating diabetesUS8829185Mar 7, 2012Sep 9, 2014Bayer Healthcare LlcSubstituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisUS8835654Sep 20, 2011Sep 16, 2014Bhi Limited PartnershipMethod and compositions for treating amyloid-related diseasesUS8871935Dec 11, 2012Oct 28, 2014Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS8883750Oct 18, 2012Nov 11, 2014Gilead Sciences, Inc.Method of treating diabetesUS8911742Jan 12, 2012Dec 16, 2014The United States Of America As Represented By The Secretary Of The ArmyTranscutaneous immunization without heterologous adjuvantUS8927574Dec 13, 2012Jan 6, 2015Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS8933022Mar 1, 2012Jan 13, 2015Jds Therapeutics, LlcMethods and compositions for the treatment and prevention Hypoglycemia and related disordersUS8952034Jul 26, 2010Feb 10, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS8962610Jun 29, 2012Feb 24, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS8968706Jul 1, 2013Mar 3, 2015Robert I. HenkinMethods for diagnosing and treating loss or distortion of tasteUS8969372Nov 15, 2004Mar 3, 2015Aptose Boisciences Inc.Aryl imidazoles and their use as anti-cancer agentsUS8974813Jun 27, 2007Mar 10, 2015Ferring B.V.Hydrophilic polyurethane compositionsUS8987305Feb 27, 2013Mar 24, 2015Aptose Biosciences Inc.2,4,5-trisubstituted imidazoles and their use as anti-microbial agentsUS9005637Apr 5, 2013Apr 14, 2015Jds Therapeutics, LlcMultiple unit dosage form having a therapeutic agent in combination with a nutritional supplementUS9018221Dec 20, 2013Apr 28, 2015Gilead Calistoga, LlcPhosphatidylinositol 3-kinase inhibitorsUS9029384Dec 20, 2013May 12, 2015Gilead Calistoga, LLC.Phosphatidylinositol 3-kinase inhibitorsUS9044404Feb 26, 2013Jun 2, 2015Allergan, Inc.Melanin modification compositions and methods of useUS9045428Aug 6, 2013Jun 2, 2015Gilead Sciences, Inc.Substituted heterocyclic compoundsUS9045457Oct 3, 2013Jun 2, 2015Sarcode Bioscience Inc.Compositions and methods for treatmentUS9045458May 12, 2014Jun 2, 2015Sarcode Bioscience Inc.Compositions and methods for treatmentUS9051297May 12, 2014Jun 9, 2015Sarcode Bioscience Inc.Compositions and methods for treatmentUS9079901Mar 17, 2014Jul 14, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS9085553Jul 25, 2013Jul 21, 2015SARcode Bioscience, Inc.LFA-1 inhibitor and methods of preparation and polymorph thereofUS9115096May 8, 2012Aug 25, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS9119835Nov 18, 2011Sep 1, 2015JDS Therapeautics, LLCMethods and compositions for the sustained release of chromiumUS9125816Aug 13, 2013Sep 8, 2015Besins Healthcare Inc.Pharmaceutical composition and method for treating hypogonadismUS9132089Jul 15, 2013Sep 15, 2015Besins Healthcare Inc.Pharmaceutical composition and method for treating hypogonadismUS9132134Nov 26, 2014Sep 15, 2015Neurogastrx, Inc.Methods for treating GI tract disordersUS9186341Aug 9, 2012Nov 17, 2015Feng XuGABA conjugates and methods of use thereofUS9193694Sep 26, 2013Nov 24, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS9216174Aug 19, 2013Dec 22, 2015Sarcode Bioscience Inc.Modulators of cellular adhesionUS9221795Jun 13, 2014Dec 29, 2015Gilead Sciences, Inc.Phosphatidylinositol 3-kinase inhibitorsUS9248126Aug 19, 2013Feb 2, 2016Sarcode Bioscience Inc.Modulators of cellular adhesionUS9266878Apr 14, 2015Feb 23, 2016Gilead Calistoga LlcPhosphatidylinositol 3-kinase inhibitorsUS9290497Jul 9, 2014Mar 22, 2016Infinity Pharmaceuticals, Inc.Processes for preparing isoquinolinones and solid forms of isoquinolinonesUS9295675Jun 17, 2014Mar 29, 2016Upsher-Smith Laboratories, Inc.Testosterone gel compositions and related methodsUS9309247Mar 20, 2014Apr 12, 2016Lorus Therapeutics Inc.2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancerUS9321749Jul 25, 2013Apr 26, 2016Globavir Biosciences, Inc.Heterocyclic compounds and uses thereofUS9353088Dec 1, 2014May 31, 2016Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereofUS9358206Sep 11, 2013Jun 7, 2016CPEX Pharmaceutical, Inc.Pharmaceutical composition and methods for peptide treatmentUS9371329May 9, 2014Jun 21, 2016Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS9376424Jul 1, 2011Jun 28, 2016Azevan Pharmaceuticals, Inc.Methods for treating post traumatic stress disorderUS9403782Jul 24, 2015Aug 2, 2016Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsUS9409889Mar 27, 2013Aug 9, 2016Bayer Pharma AktiengesellschaftAmino-substituted imidazopyridazinesUS9416362May 16, 2014Aug 16, 2016The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for reducing viral genome amounts in a target cellUS9421170Mar 9, 2015Aug 23, 2016Jds Therapeutics, LlcMultiple unit dosage form having a therapeutic agent in combination with a nutritional supplementUS9452215Feb 21, 2013Sep 27, 2016The Regents Of The University Of ColoradoBourvadin derivatives and therapeutic uses thereofUS9499480Apr 7, 2014Nov 22, 2016Bhi Limited PartnershipMethods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acidUS9499547Sep 5, 2012Nov 22, 2016Bayer Intellectual Property GmbhAmino-substituted imidazopyridazinesUS20020068717 *Sep 12, 2001Jun 6, 2002Borrelli Michael J.Methods and compositions for enhancing diffusion of therapeutic agents through tissueUS20020086284 *Nov 6, 2001Jul 4, 2002Coffey Matthew C.Methods for the treatment of cellular proliferative disordersUS20020150566 *Mar 25, 2002Oct 17, 2002Kun-Liang GuanMethod of inhibiting cancerous cell proliferation using Ras mutants of GDP-bound conformationUS20020187954 *Apr 17, 2002Dec 12, 2002Genesense Technologies Inc.Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to modulate cell growthUS20030022877 *May 21, 2002Jan 30, 2003Dudley Robert E.Method of increasing testosterone and related steroid concentrations in womenUS20030045492 *Apr 5, 2002Mar 6, 2003Tang De-Chu C.Vaccination by topical application of recombinant vectorsUS20030049307 *Feb 16, 2001Mar 13, 2003Gyurik Robert J.Pharmaceutical compositionUS20030049838 *Aug 30, 2002Mar 13, 2003Stem Cell Therapeutics Inc.Combined regulation of neural cell productionUS20030054023 *Oct 31, 2002Mar 20, 2003Photogenesis, Inc.Volute subretinal implantsUS20030054551 *Aug 30, 2002Mar 20, 2003Stem Cell Therapeutics Inc.Effect of growth hormone and IGF-1 on neural stem cellsUS20030054993 *Apr 8, 2002Mar 20, 2003Rancourt Derrick E.Implantation serine proteinasesUS20030054998 *Aug 30, 2002Mar 20, 2003Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbersUS20030125278 *Jan 18, 2002Jul 3, 2003Tang De-Chu C.Immunization of animals by topical applications of a salmonella-based vectorUS20030171259 *Mar 3, 2003Sep 11, 2003Pankaj ModiMethod for administering insulin to the buccal regionUS20030199688 *Aug 23, 2002Oct 23, 2003Josh KrieselMacrocyclic module compositionsUS20030215443 *Mar 28, 2003Nov 20, 2003Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS20030220344 *Apr 3, 2003Nov 27, 2003Luiz BelardinelliMethod of treating arrhythmiasUS20040001853 *Feb 13, 2003Jan 1, 2004Rajan GeorgeChimeric antigens for eliciting an immune responseUS20040002482 *Mar 15, 2002Jan 1, 2004Dudley Robert E.Androgen pharmaceutical composition and method for treating depressionUS20040009936 *Jan 16, 2003Jan 15, 2004Tang De-Chu C.Vaccine and drug delivery by topical application of vectors and vector extractsUS20040009948 *May 29, 2003Jan 15, 2004Genesense Technologies Inc.Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductaseUS20040033964 *Nov 16, 2001Feb 19, 2004Darren MagdaTexaphyrin coordination compounds and uses thereofUS20040087482 *Jan 15, 2002May 6, 2004Oregon Health And Sciences UniversityMicroparticle-drug conjugates for biological targetingUS20040091458 *May 8, 2003May 13, 2004Oncolytics Biotech Inc.Method for reducing pain using oncolytic virusesUS20040092448 *Jul 31, 2003May 13, 2004Shigeki OhtaMethod of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)US20040092494 *May 21, 2002May 13, 2004Dudley Robert E.Method of increasing testosterone and related steroid concentrations in womenUS20040106741 *Apr 29, 2003Jun 3, 2004Kriesel Joshua W.Nanofilm compositions with polymeric componentsUS20040138243 *May 27, 2003Jul 15, 2004Konradi Andrei W.Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrinsUS20040142954 *May 27, 2003Jul 22, 2004Konradi Andrei W.Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrinsUS20040146491 *Nov 6, 2003Jul 29, 2004Norman Kara L.Reovirus for the treatment of ral-mediated cellular proliferative disordersUS20040146534 *Feb 13, 2002Jul 29, 2004Glenn Gregory M.Vaccine for transcutaneous immunizationUS20040162253 *Sep 12, 2003Aug 19, 2004Replicor, Inc.Antiviral oligonucleotides targeting HBVUS20040162254 *Sep 12, 2003Aug 19, 2004Replicor, Inc.Antiviral oligonucleotides targeting HSV and CMVUS20040170959 *Sep 12, 2003Sep 2, 2004Replicor, Inc.Methods for identifying antiviral oligonucleotidesUS20040171602 *Sep 10, 2003Sep 2, 2004Pharmacyclics, Inc.Novel metallotexaphyrin derivativesUS20040176476 *Jun 24, 2002Sep 9, 2004Gyurik Robert J.Pharmaceutical compositionUS20040258703 *Jul 21, 2004Dec 23, 2004The Government Of The Us, As Represented By The Secretary Of The ArmySkin-active adjuvants for transcutaneous immunizationUS20040260085 *Feb 7, 2003Dec 23, 2004Kriesel Joshua W.Nanofilm and membrane compositionsUS20050013828 *Aug 5, 2004Jan 20, 2005Virexx Medical Corp.Chimeric antigens for eliciting an immune responseUS20050014230 *Jul 16, 2003Jan 20, 2005Ccl Holding Co., Ltd.Preparation of fully human antibodiesUS20050019308 *Jul 6, 2004Jan 27, 2005Oncolytics Biotech Inc.Oncolytic viruses for the treatment of neoplasms having activated PP2A or RacUS20050020552 *Jul 15, 2004Jan 27, 2005Chaim AschkenasyPharmaceutical composition and method for transdermal drug deliveryUS20050025833 *Jul 15, 2004Feb 3, 2005Chaim AschkenasyPharmaceutical composition and method for transdermal drug deliveryUS20050031628 *Aug 5, 2004Feb 10, 2005Virexx Medical Corp.Chimeric antigens for breaking host tolerance to foreign antigensUS20050036953 *May 21, 2004Feb 17, 2005Moshe ArkinTopical compositions of ammonium lactateUS20050037040 *May 21, 2004Feb 17, 2005Moshe ArkinTopical compositions of urea and ammonium lactateUS20050038117 *Jun 18, 2004Feb 17, 2005Neurochem (International) LimitedMethods and compositions for treating amyloid-related diseasesUS20050042182 *May 21, 2004Feb 24, 2005Moshe ArkinTopical compositions of ureaUS20050042268 *Jul 15, 2004Feb 24, 2005Chaim AschkenasyPharmaceutical composition and method for transdermal drug deliveryUS20050063954 *Aug 11, 2004Mar 24, 2005Oncolytics Biotech Inc., A Canada CorporationReovirus for the treatment of cellular proliferative disordersUS20050096385 *Jun 18, 2004May 5, 2005Xianqi KongMethods and compositions for treating amyloid-related diseasesUS20050119290 *May 27, 2003Jun 2, 2005Konradi Andrei W.Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrinsUS20050123592 *Dec 2, 2004Jun 9, 2005Gyurik Robert J.Pharmaceutical compositions and methods for insulin treatmentUS20050130999 *May 27, 2003Jun 16, 2005Konradi Andrei W.Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrinsUS20050137152 *Dec 19, 2003Jun 23, 2005Danny CheungReovirus for the prevention of neoplasiaUS20050153912 *Sep 12, 2003Jul 14, 2005Replicor, Inc.Antiviral oligonucleotides targeting viral familiesUS20050176661 *Sep 12, 2003Aug 11, 2005Replicor, Inc.Antiviral oligonucleotidesUS20050192260 *Apr 21, 2003Sep 1, 2005Gyurik Robert J.Pharmaceutical compositionUS20050203162 *Mar 11, 2005Sep 15, 2005Miikana Therapeutics CorporationCytotoxic agents and methods of useUS20050232867 *Mar 5, 2004Oct 20, 2005Gyurik Robert JPharmaceutical compositions and methods for peptide treatmentUS20050245436 *Feb 14, 2005Nov 3, 2005Stem Cell Therapeutics Corp.Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesisUS20050287157 *Jun 3, 2005Dec 29, 2005Iomai CorporationDry formulation for transcutaneous immunizationUS20060002959 *Apr 20, 2005Jan 5, 2006Government Of The United StatesSkin-sctive adjuvants for transcutaneous immuizationUS20060008461 *Feb 22, 2005Jan 12, 2006Yatvin Milton BMicroparticle-drug conjugates for biological targetingUS20060045925 *Aug 31, 2004Mar 2, 2006Shih-Lan HsuPharmaceutical use of Graptopetalum and related plantsUS20060073166 *Oct 21, 2005Apr 6, 2006Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS20060088869 *Oct 20, 2005Apr 27, 2006Oncolytics Biotech Inc.Viral purification methodsUS20060094063 *Nov 4, 2005May 4, 2006Sytera, Inc.Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formationUS20060099714 *Oct 25, 2005May 11, 2006Sytera, Inc.Detection and analysis of ophthalmically-relevant fluorescent moleculesUS20060111307 *Nov 16, 2005May 25, 2006Wendye RobbinsMethods and compositions for treating painUS20060111308 *Nov 16, 2005May 25, 2006Wendye RobbinsMethods and compositions for therapeutic treatmentUS20060128638 *Feb 6, 2006Jun 15, 2006Pharmacyclics, Inc.Texaphyrin coordination compounds and uses thereofUS20060148084 *Mar 1, 2006Jul 6, 2006Stem Cell Therapeutics Inc.Effect of growth hormone and IGF-1 on neural stem cellsUS20060165724 *Mar 27, 2006Jul 27, 2006Oncolytics Biotech Inc.Method of producing infectious reovirusUS20060166957 *Jun 13, 2004Jul 27, 2006Menachem RubinsteinMethods of treating obesity and related disorders using tellurium selenium compoundsUS20060167057 *Nov 16, 2005Jul 27, 2006Xianqi KongCompounds for the treatment of CNS and amyloid associated diseasesUS20060167088 *Jun 10, 2005Jul 27, 2006Sytera, Inc.Methods and compositions for treating ophthalmic conditions with retinyl derivativesUS20060172288 *Mar 31, 2006Aug 3, 2006Oncolytics Biotech Inc.Methods for the treatment of cellular proliferative disordersUS20060181579 *Feb 14, 2006Aug 17, 2006Brother Kogyo Kabushiki KaishaInkjet Recording ApparatusUS20060183800 *Nov 14, 2005Aug 17, 2006Xianqi KongMethods and fluorinated compositions for treating amyloid-related diseasesUS20060223855 *Dec 21, 2005Oct 5, 2006Neurochem (International) LimitedMethods and compositions for treating amyloid-related diseasesUS20060233761 *Feb 23, 2006Oct 19, 2006Arnold John JAlkyl-glycoside enhanced vaccinationUS20060269593 *Jan 19, 2006Nov 30, 2006The Government Of The United StatesAdjuvant for transcutaneous immunizationUS20060275801 *May 1, 2006Dec 7, 2006Henkin Robert IMethods for detection of biological substancesUS20060281739 *May 17, 2006Dec 14, 2006Thomas GadekCompositions and methods for treatment of eye disordersUS20060287275 *Aug 24, 2006Dec 21, 2006Prabha IbrahimPartial and full agonists of A1 adenosine receptorsUS20060293283 *Jun 14, 2006Dec 28, 2006Rao KallaProdrugs of A2B adenosine receptor antagonistsUS20070010544 *Jun 28, 2006Jan 11, 2007Matthew AbelmanABCA1 elevating compoundsUS20070010573 *Dec 21, 2005Jan 11, 2007Xianqi KongMethods and compositions for treating amyloid-related diseasesUS20070015827 *Jul 10, 2006Jan 18, 2007Sytera, Inc.Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulationUS20070066560 *Nov 15, 2006Mar 22, 2007Elfatih ElzeinPartial and full agonists of A1 adenosine receptorsUS20070071705 *Sep 29, 2005Mar 29, 2007De Oliveira Monica A MTopical anti-microbial compositionsUS20070072838 *Sep 26, 2005Mar 29, 2007Pharmacyclics, Inc.High-purity texaphyrin metal complexesUS20070078119 *Sep 30, 2005Apr 5, 2007Pharmacyclics, Inc.Storage system for texaphyrin pharmaceutical formulationsUS20070086984 *Nov 7, 2006Apr 19, 2007Oncolytics Biotech Inc.Viruses for the Treatment of Cellular Proliferative DisordersUS20070087977 *Oct 27, 2006Apr 19, 2007Wendye RobbinsMethods and compositions for treating painUS20070087994 *Oct 11, 2006Apr 19, 2007Elfatih ElzeinA1 adenosine receptor agonistsUS20070098698 *Sep 27, 2006May 3, 2007Stem Cell Therapeutics Corp.Pregnancy-induced Oligodendrocyte Precursor Cell Proliferation Regulated by ProlactinUS20070099921 *Oct 16, 2006May 3, 2007Elan PharmaceuticalsHeteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4US20070105929 *Aug 19, 2003May 10, 2007Raed Al-Qawasmeh2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial AgentsUS20070111932 *Jul 31, 2003May 17, 2007Stem Cell Therapeutics Inc.Method of enhancing and/or inducing neuronal migration using erythropoietinUS20070123553 *Nov 15, 2004May 31, 2007Lorus Therapeutics Inc.Aryl imidazoles and their use as anti-cancer agentsUS20070129390 *Sep 28, 2006Jun 7, 2007Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4US20070142416 *Sep 28, 2006Jun 21, 2007Elan Pharmaceuticas, Inc.Pyrimidinyl amide compounds with inhibit leukocyte adhesion mediated by VLA-4US20070179092 *Jan 24, 2007Aug 2, 2007Stem Cell Therapeutics Inc.Method of Enhancing Neural Stem Cell Proliferation, Differentiation, and Survival Using Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)US20070185051 *Dec 18, 2006Aug 9, 2007Arvinder DhallaPartial and full agonists of A1 adenosine receptorsUS20070190032 *Feb 9, 2007Aug 16, 2007Oncolytics Biotech Inc.Use of Local Immune Suppression to Enhance Oncolytic Viral TherapyUS20070208040 *Mar 2, 2007Sep 6, 2007Elfatih ElzeinA2a adenosine receptor antagonistsUS20070219174 *Mar 15, 2006Sep 20, 2007Pharmacyclics, Inc.Methods of treating cancer using hypofractionated radiation and texaphyrinsUS20070232556 *Mar 31, 2006Oct 4, 2007Montine Thomas JMethods and compositions for the treatment of neurological diseases and disordersUS20070249537 *Apr 27, 2007Oct 25, 2007Supernus Pharmaceuticals, Inc.Absorption enhancing agentsUS20070254953 *Mar 12, 2007Nov 1, 2007Perrigo Israel Pharmaceuticals Ltd.Topical compositions of urea and ammonium lactateUS20080009503 *May 31, 2007Jan 10, 2008Andrew WolffMethod of treating diabetesUS20080015180 *May 30, 2007Jan 17, 2008Neurochem (International) LimitedMethods and compositions for treating amyloid-related diseasesUS20080019980 *May 30, 2007Jan 24, 2008Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS20080031886 *May 30, 2007Feb 7, 2008Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersUS20080039389 *Mar 16, 2007Feb 14, 2008Stem Cell Therapeutics Corp.Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disordersUS20080045446 *Jun 8, 2007Feb 21, 2008Gyurik Robert JInsulin compositionUS20080045447 *Jun 8, 2007Feb 21, 2008Gyurik Robert JFibrilliform-free insulin compositionUS20080057073 *May 30, 2007Mar 6, 2008Coffey Matthew CMethods for the treatment of cellular proliferative disordersUS20080058357 *Feb 26, 2007Mar 6, 2008Elan Pharmaceuticals, Inc.Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4US20080069865 *Jan 13, 2005Mar 20, 2008Southard Jeffrey LControlled Release Cgrp Delivery Composition for Cardiovascular and Renal IndicationsUS20080075729 *May 30, 2007Mar 27, 2008Oncolytics Biotech Inc.Methods for preventing reovirus recognition for the treatment of cellular proliferative disordersUS20080081032 *Jun 1, 2007Apr 3, 2008Oncolytics Biotech Inc.Method for reducing pain using oncolytic virusesUS20080103120 *Oct 30, 2007May 1, 2008Bentley Phamaceuticals, IncPharmaceutical compositionUS20080107735 *Nov 2, 2006May 8, 2008Gyurik Robert JMacrocyclic formulations for transmembrane drug deliveryUS20080108590 *Oct 31, 2007May 8, 2008Bentley Pharmaceuticals, Inc.Pharmaceutical CompositionUS20080109040 *Oct 31, 2007May 8, 2008Luiz BelardinelliMethod of treating arrhythmiasUS20080131494 *Oct 30, 2007Jun 5, 2008Acrux Dds Pty Ltd.Dermal Penetration enhancers and drug delivery systems involving sameUS20080139570 *Oct 5, 2007Jun 12, 2008Jeffrey ChisholmBICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20080152597 *Oct 5, 2007Jun 26, 2008Acrux Dds Pty Ltd.Dermal penetration enhancers and drug delivery systems involving the sameUS20080160065 *Jul 12, 2007Jul 3, 2008Janet Anne HallidayDrug delivery polymer with hydrochloride salt of clindamycinUS20080161282 *Sep 17, 2007Jul 3, 2008Xiao-Yi XiaoCytotoxic agents and methods of useUS20080176896 *Oct 29, 2007Jul 24, 2008Wang ShenModulators of cellular adhesionUS20080181873 *Mar 19, 2008Jul 31, 2008Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbersUS20080182839 *Nov 1, 2007Jul 31, 2008Sunesis Pharmaceuticals, Inc.Modulators of cellular adhesionUS20080200462 *Nov 8, 2007Aug 21, 2008Novartis AgSubstituted pyrazole and triazole compounds as ksp inhibitorsUS20080207589 *Jan 3, 2008Aug 28, 2008Novartis AgCyclized derivatives as eg-5 inhibitorsUS20080233142 *May 24, 2007Sep 25, 2008Government Of The United States, As Represented By Secretary Of The ArmyUse of penetration enhancers and barrier disruption methods to enhance the immune response of an antigenUS20080248531 *Jan 29, 2007Oct 9, 2008Ccl Holdings Co., Ltd., A Taiwan CorporationPreparation of fully human antibodiesUS20080249074 *Nov 3, 2006Oct 9, 2008Laboratorios Belmac, S.A.Composition for the Transdermal Administration of Physiologically Active AgentsUS20080249100 *Oct 5, 2007Oct 9, 2008Jeffrey ChisholmPTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20080255130 *Apr 9, 2008Oct 16, 2008Dmitry KoltunBicyclic Nitrogen-containing Heterocyclic compounds for use as Stearoyl CoA Desaturase inhibitorsUS20080255161 *Apr 9, 2008Oct 16, 2008Dmitry Koltun3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20080262015 *Nov 15, 2004Oct 23, 2008Lorus Therapeutics Inc.Aryl imidazoles and their use as anti-cancer agentsUS20080275012 *Oct 30, 2007Nov 6, 2008Bentley Phamaceuticals, Inc.Pharmaceutical CompositionUS20080275013 *Oct 31, 2007Nov 6, 2008Bentley Pharmaceuticals, Inc.Pharmaceutical CompositionUS20080280870 *Jul 18, 2006Nov 13, 2008Azevan Pharmaceuticals, Inc.Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin AntagonistsUS20080292594 *May 21, 2008Nov 27, 2008Oncolytics Biotech Inc.Mutant reoviruses and methods of making and usingUS20080311126 *Jan 12, 2005Dec 18, 2008Genesense Technologies, IncAntisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of CancerUS20090012103 *Jul 3, 2008Jan 8, 2009Matthew AbelmanSubstituted heterocyclic compoundsUS20090023643 *Jan 13, 2005Jan 22, 2009Vasogenix Pharmaceuticals, Inc.Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The SameUS20090042827 *Jul 10, 2008Feb 12, 2009Andrew VaillantAntiviral oligonucleotides targeting hbvUS20090081205 *Mar 16, 2007Mar 26, 2009Stem Cell Therapreutics CorpContinuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agentsUS20090081244 *Jan 25, 2008Mar 26, 2009Army, Gov. Of The Us, As Represented By TheDry Formulation for Transcutaneous ImmunizationUS20090088394 *Sep 4, 2008Apr 2, 2009Wendye RobbinsMethods and compositions for therapeutic treatmentUS20090099110 *Feb 28, 2008Apr 16, 2009Andrew VaillantAntiviral oligonucleotidesUS20090105283 *Oct 15, 2008Apr 23, 2009Dmitry Koltun3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20090117082 *Nov 25, 2008May 7, 2009Oncolytics Biotech Inc.Reovirus for the Treatment of Cellular Proliferative DisordersUS20090118251 *Jan 23, 2009May 7, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS20090118252 *Jan 23, 2009May 7, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS20090155176 *Oct 17, 2008Jun 18, 2009Sarcode CorporationCompositions and methods for treatment of diabetic retinopathyUS20090156527 *Apr 9, 2008Jun 18, 2009Andrew VaillantAntiviral oligonucleotides targeting viral familiesUS20090192131 *Mar 19, 2009Jul 30, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical CompositionUS20090192132 *Mar 19, 2009Jul 30, 2009Cpex Pharmaceuticals, Inc.Pharmaceutical CompositionUS20090192181 *Jan 12, 2009Jul 30, 2009Elan Pharmaceuticals, Inc.Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4US20090203689 *Feb 6, 2009Aug 13, 2009Arvinder DhallaAbca-1 elevating compounds and methodsUS20090253738 *Apr 3, 2009Oct 8, 2009Dmitry KoltunTRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20090257957 *Apr 15, 2009Oct 15, 2009John BurnierAerosolized LFA-1 antagonists for use in localized treatment of immune related disordersUS20090258069 *Apr 15, 2009Oct 15, 2009John BurnierDelivery of LFA-1 antagonists to the gastrointestinal systemUS20090258070 *Apr 15, 2009Oct 15, 2009John BurnierTopical LFA-1 antagonists for use in localized treatment of immune related disordersUS20090274668 *Jul 16, 2009Nov 5, 2009Stem Cell Therapeutics IncCombined Regulation of Neural Cell ProductionUS20090291120 *Jun 27, 2007Nov 26, 2009Jukka TuominenHydrophilic Polyurethane CompositionsUS20090298869 *Apr 15, 2009Dec 3, 2009John BurnierCrystalline pharmaceutical and methods of preparation and use thereofUS20090324502 *Jun 5, 2009Dec 31, 2009Cpex Pharmaceuticals, Inc.Nasal Formulations of InsulinUS20090324692 *Jun 27, 2007Dec 31, 2009Controlled Therapeutics (Scotland) LimitedPolyurethane ElastomersUS20090325896 *Jul 23, 2009Dec 31, 2009Prabha IbrahimPartial and full agonists of a1 adenosine receptorsUS20100004255 *Sep 9, 2009Jan 7, 2010Luiz BelardinelliMethod of treating arrhythmiasUS20100016274 *Sep 14, 2007Jan 21, 2010Koppel Gary ABeta-lactam cannabinoid receptor modulatorsUS20100016345 *Jul 17, 2009Jan 21, 2010Elan Pharmaceuticals, Inc.Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4US20100022563 *Jul 23, 2009Jan 28, 2010Henkin Robert IPhosphodiesterase inhibitor treatmentUS20100029701 *Oct 2, 2007Feb 4, 2010Nantermet Philippe GMacrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's diseaseUS20100034813 *Nov 8, 2007Feb 11, 2010Yi XiaSubstituted pyrazole and triazole compounds as ksp inhibitorsUS20100055056 *Sep 4, 2008Mar 4, 2010Sato Pharmaceutical Co., Ltd.Agent for improving permeation of a drug into a nail and an external treating agent containing the sameUS20100056538 *Nov 13, 2009Mar 4, 2010Gilead Palo Alto, Inc.Pro-drugs of A2B Adenosine Receptor AntagonistsUS20100063112 *Nov 3, 2007Mar 11, 2010Bayer Schering Pharma AktiengesellschaftPolymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamideUS20100081640 *Sep 30, 2009Apr 1, 2010Cpex Pharmaceuticals, Inc.Pharmaceutical compositionUS20100093693 *Aug 6, 2009Apr 15, 2010Wang ShenModulators of cellular adhesionUS20100113434 *Oct 15, 2009May 6, 2010Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4US20100113463 *Jan 7, 2010May 6, 2010Gilead Palo Alto, Inc.PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20100113497 *Oct 8, 2009May 6, 2010Kyphia Pharmaceuticals, Inc.Gaba conjugates and methods of use thereofUS20100113533 *Nov 3, 2007May 6, 2010Bayer Schering Pharma AktiengesellschaftPolymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-CarboxamideUS20100113591 *Nov 5, 2009May 6, 2010Bellus Health (International) LimitedMethods and compositions for treating amyloid-related diseasesUS20100120727 *Nov 12, 2009May 13, 2010Kyphia Pharmaceuticals, Inc.Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use ThereofUS20100125073 *Aug 28, 2007May 20, 2010Olaf WeberBenzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous systemUS20100137188 *Sep 27, 2007Jun 3, 2010Paolo BottiFormulations comprising cyclic compoundsUS20100160214 *Dec 22, 2009Jun 24, 2010Serenity Pharmaceuticals CorporationDesmopressin compositionUS20100160341 *Dec 22, 2009Jun 24, 2010Elan Pharmaceuticals, Inc.Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4US20100160343 *Dec 14, 2009Jun 24, 2010Elan Pharmaceuticals, Inc.Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4US20100172965 *Dec 21, 2009Jul 8, 2010Vaiilant AndrewAntiviral oligonucleotides targeting viral familiesUS20100173953 *Sep 29, 2007Jul 8, 2010Alfons Grunenberg4-[4-(amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrateUS20100173980 *Dec 21, 2009Jul 8, 2010Andrew VaillantAntiviral oligonucleotides targeting rsvUS20100197684 *Feb 9, 2010Aug 5, 2010Gilead Palo Alto, Inc.Substituted heterocyclic compoundsUS20100197701 *Apr 7, 2010Aug 5, 2010Gilead Palo Alto, Inc.Method of treating diabetesUS20100203105 *Feb 3, 2010Aug 12, 2010Generex Pharmaceuticals IncorporatedMethod for administering insulin to the buccal regionUS20100204238 *Apr 26, 2010Aug 12, 2010Gilead Palo Alto, Inc.BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20100210579 *Mar 15, 2010Aug 19, 2010Gilead Palo Alto, Inc.Partial and full agonists of a1 adenosine receptorsUS20100227875 *Dec 29, 2009Sep 9, 2010Henkin Robert IMethods for detection of biological substancesUS20100239691 *Jun 20, 2008Sep 23, 2010The Uab Research FoundationModulating latency and reactivation of mycobacterium tuberculosisUS20100256187 *Apr 2, 2010Oct 7, 2010Colucid Pharmaceuticals, Inc.Composition of 2,4,6- trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamideUS20100267752 *Oct 14, 2009Oct 21, 2010Gilead Palo Alto, Inc.3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORSUS20100278812 *Jun 4, 2010Nov 4, 2010Cpex Pharmaceuticals, Inc.Nasal immunizationUS20100292217 *May 13, 2010Nov 18, 2010Gilead Palo Alto, Inc.Ranolazine for the treatment of cns disordersUS20100316626 *Aug 10, 2007Dec 16, 2010The Government Of The United States Of America As Represented By The SecretaryMethods for treatment and diagnosis of psychiatric disordersUS20110003791 *Sep 15, 2010Jan 6, 2011Rustum BoyceCyclized Derivatives as EG-5 InhibitorsUS20110009407 *Apr 27, 2010Jan 13, 2011Elan Pharmaceuticals, Inc.Pyridinone antagonists of alpha-4 integrinsUS20110014155 *Jul 22, 2010Jan 20, 2011Oncolytics Biotech Inc.Reovirus for the Treatment of Cellular Proliferative DisordersUS20110021521 *Jul 26, 2010Jan 27, 2011Gilead Palo Alto, Inc.Fused heterocyclic compounds as ion channel modulatorsUS20110038852 *Jun 9, 2010Feb 17, 20113-V Biosciences, Inc.Antivirals that target transporters, carriers, and ion channelsUS20110059935 *Aug 25, 2010Mar 10, 2011Azevan Pharmaceuticals, IncBeta-LACTAMYL VASOPRESSIN V1a ANTAGONISTSUS20110070200 *May 27, 2009Mar 24, 2011Oncolytics Biotech Inc.Abrogating proinflammatory cytokine production during oncolytic reovirus therapyUS20110086005 *May 27, 2009Apr 14, 2011Oncolytics Biotech Inc.Modulating interstitial pressure and oncolytic viral delivery and distributionUS20110091488 *Jul 13, 2010Apr 21, 2011Controlled Therapeutics (Scotland) LimitedWater-swellable polymersUS20110092707 *Oct 21, 2010Apr 21, 2011Sarcode CorporationCrystalline Pharmaceutical and Methods of Preparation and Use ThereofUS20110097363 *Oct 12, 2010Apr 28, 2011Cpex Pharmaceuticals, Inc.Therapeutically Effective Preparations of InsulinUS20110111014 *Jun 26, 2008May 12, 2011Parkinson's InstituteMethods and compositions for treatment of neurological disordersUS20110124625 *Feb 4, 2011May 26, 2011Sarcode CorporationModulators of Cellular AdhesionUS20110124669 *Feb 4, 2011May 26, 2011Sarcode CorporationModulators of Cellular AdhesionUS20110124707 *Nov 19, 2010May 26, 2011The Board Of Trustees Of The Leland Stanford Junior UniversityMethods And Compositions For Reducing Viral Genome Amounts In A Target CellUS20110152337 *Dec 22, 2010Jun 23, 2011Lorus Therapeutics Inc.2,4,5-trisubstituted imidazoles and their use as anti-microbial agentsUS20110160162 *Jan 21, 2011Jun 30, 2011Gilead Sciences, Inc.Prodrugs of a2b adenosine receptor antagonistsUS20110166166 *Jan 31, 2008Jul 7, 2011Henkin Robert IMethods for detection of biological substancesUS20110178009 *Oct 29, 2010Jul 21, 2011Stem Cell Therapeutics Corp.Pheromones and the Luteinizing Hormone for Inducing Proliferation of Neural Stem Cells and NeurogenesisUS20110223185 *May 18, 2011Sep 15, 2011Rajan GeorgeChimeric hepatitis c virus antigens for eliciting an immune responseUSRE40812Feb 5, 2004Jun 30, 2009Unigene Laboratories Inc.Nasal calcitonin formulationUSRE43580Jun 29, 2009Aug 14, 2012Unigene Laboratories, Inc.Nasal calcitonin formulationsCN1662243BApr 21, 2003Oct 26, 2011Cpex药品公司Pharmaceutical compositionCN1913912BDec 2, 2004Jun 16, 2010Cpex药品公司Pharmaceutical compositions and methods for insulin treatmentCN101541346BSep 27, 2007Jul 2, 2014保罗·博蒂Formulations comprising cyclic compoundsEP0689839A2Jun 28, 1995Jan 3, 1996Eli Lilly And CompanyUse of inhibitors of adenosine triphosphatase for the manufacture of a medicament for the treatment of disorders anociated with beta-amyloid peptideEP0694535A1Apr 24, 1995Jan 31, 1996Eli Lilly And CompanyNon-peptidyl tachykinin receptor antagonistsEP0709090A2Oct 13, 1995May 1, 1996Eli Lilly And CompanyCompositions for treating resistant tumorsEP0714894A1Nov 23, 1995Jun 5, 1996Eli Lilly And Company3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonistsEP0773217A1Nov 4, 1996May 14, 1997Eli Lilly And CompanyBenzothiphene derivatives for treating resistant tumorsEP1425019A1 *Apr 21, 2003Jun 9, 2004Bentley Pharmaceuticals, Inc.Pharmaceutical compositionEP1425019A4 *Apr 21, 2003Nov 17, 2004Bentley Pharmaceuticals IncPharmaceutical compositionEP1741433A1 *Apr 21, 2003Jan 10, 2007Bentley Pharmaceuticals, Inc.Pharmaceutical composition comprising an androgenEP1769785A1 *Feb 19, 1997Apr 4, 2007Acrux DDS Pty LtdDermal penetration enhancers and drug delivery systems involving sameEP1930007A1Apr 4, 2003Jun 11, 2008Cv Therapeutics, Inc.Use of ranolazine for the preparation of a medicament for the treatment of arrhythmiasEP1944035A1May 7, 2003Jul 16, 2008Oncolytics Biotech Inc.Method for reducing pain using oncolytic virusesEP1949905A1Feb 18, 2000Jul 30, 2008Oncolytics Biotech, Inc.Reovirus for the treatment of cellular proliferative disordersEP1955703A1Nov 8, 2000Aug 13, 2008Oncolytics Biotech Inc.Viruses for the treatment of cellular proliferative disordersEP1977746A1Apr 2, 2008Oct 8, 2008The Parkinson's InstituteMethods and compositions for reduction of side effects of therapeutic treatmentsEP1982970A1Mar 28, 2008Oct 22, 2008Chevron U.S.A. Inc.Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disordersEP1994927A1Mar 31, 2008Nov 26, 2008Chevron U.S.A. Inc.Diamondoid derivatives possessing therapeutic activity in the treatment of viral disordersEP1995227A1Mar 31, 2008Nov 26, 2008Chevron U.S.A. Inc.Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disordersEP2025336A1Jun 6, 2005Feb 18, 2009Sirion Therapeutics, Inc.Retinyl derivatives for treating ophtalmic conditionsEP2033633A2Feb 15, 2001Mar 11, 2009Cv Therapeutics, Inc.Partial fatty acid oxidation inhibitors in the treatment of congestive heart failureEP2087892A2Jun 22, 2000Aug 12, 2009Pharmacia & Upjohn Company LLC(S,S) reboxetine for treating age associated learning and mental disordersEP2090312A1Jun 22, 2000Aug 19, 2009Pharmacia & Upjohn Company LLC(S,S) reboxetine for treating attention deficit disorderEP2168582A1Sep 24, 2008Mar 31, 2010Bayer Schering Pharma AktiengesellschaftCombinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolinesEP2168583A1Sep 24, 2008Mar 31, 2010Bayer Schering Pharma AktiengesellschaftUse of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myelomaEP2198866A1Apr 4, 2003Jun 23, 2010Gilead Palo Alto, Inc.Use of ranolazine for the preparation of a medicament for the treatment of arrhythmiasEP2213742A1Aug 6, 2004Aug 4, 2010ViRexx Medical Corp.Chimeric antigens for breaking host tolerance to foreign antigensEP2241326A1Dec 2, 2004Oct 20, 2010CPEX Pharmaceuticals, Inc.Pharmaceutical compositions and methods for insulin treatmentEP2253701A1Mar 11, 2002Nov 24, 2010Oncolytics Biotech, Inc.Method of extracting virus from cell cultureEP2258399A2Jul 8, 2005Dec 8, 2010Elan Pharmaceuticals Inc.Multivalent VLA-4 antagonists comprising polymer moietiesEP2258400A2Jul 8, 2005Dec 8, 2010Elan Pharmaceuticals, Inc.Multivalent VLA-4 antagonists comprising polymer moietiesEP2275412A1Oct 14, 2005Jan 19, 2011Novartis Vaccines and Diagnostics, Inc.Indole and benzimidazole derivativesEP2277516A1Jun 6, 2005Jan 26, 2011ReVision Therapeutics, Inc.Retinyl derivatives for treating ophtalmic conditionsEP2283850A1Mar 7, 2005Feb 16, 2011CPEX Pharmaceuticals, Inc.Pharmaceutical compositions and methods for peptide treatmentEP2289515A2Oct 31, 2006Mar 2, 2011Bayer HealthCare LLCCombinations comprising a diaryl urea and an interferonEP2295426A1May 2, 2005Mar 16, 2011Bayer HealthCare, LLCSubstituted pyrazolyl urea derivatives useful in the treatment of cancerEP2295427A1May 2, 2005Mar 16, 2011Bayer HealthCare, LLCSubstituted pyrazolyl urea derivatives useful in the treatment of cancerEP2298356A2Jul 8, 2005Mar 23, 2011Elan Pharmaceuticals, Inc.Multivalent VLA-4 antagonists comprising polymer moietiesEP2301937A1Jun 14, 2006Mar 30, 2011Cv Therapeutics, Inc.Prodrugs of A2b adenosine receptor antagonistsEP2311462A1Oct 14, 2005Apr 20, 2011Cv Therapeutics, Inc.Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonistsEP2319531A2Oct 7, 2005May 11, 2011Stem Cell Therapeutics Corp.Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compoundsEP2322166A1Apr 2, 2008May 18, 2011Parkinson's InstituteMethods and compositions for reduction of side effects of therapeutic treatmentsEP2322167A1Apr 2, 2008May 18, 2011Parkinson's InstituteMethods and Compositions for Reduction of Side Effects of Therapeutic TreatmentsEP2322168A1Apr 2, 2008May 18, 2011Parkinson's InstituteMethods and Compositions for Reduction of Side Effects of Therapeutic TreatmentsEP2332540A1May 21, 2003Jun 15, 2011Cv Therapeutics, Inc.Administration of ranolazine for the treatment of diabetesEP2338996A2May 3, 2005Jun 29, 2011The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for reducing viral genome amounts in a target cellEP2412716A1Feb 19, 2003Feb 1, 2012Cv Therapeutics, Inc.Partial and full agonists of A1 adenosine receptorsEP2444079A1May 17, 2006Apr 25, 2012SARcode Bioscience Inc.Compositions and Methods for Treatment of Eye DisordersEP2465505A1Nov 30, 2006Jun 20, 2012Bayer HealthCare LLCSubstituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisEP2500431A2May 3, 2005Sep 19, 2012The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for reducing viral genome amounts in a target cellEP2508525A1Apr 5, 2011Oct 10, 2012Bayer Pharma AktiengesellschaftSubstituted 2,3-dihydroimidazo[1,2-c]quinazoline saltsEP2511267A1Jun 4, 2004Oct 17, 2012Elan Pharmaceuticals Inc.3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's diseaseEP2694076A1 *Mar 29, 2012Feb 12, 2014Cpex Pharmaceuticals, Inc.Nasal formulations of benzodiazepineEP2694076A4 *Mar 29, 2012Aug 27, 2014Cpex Pharmaceuticals IncNasal formulations of benzodiazepineEP2865668A2Feb 18, 2011Apr 29, 2015Siga Technologies, Inc.Inhibitors and methods of inhibiting bacterial and viral pathogensEP2918589A1Jul 15, 2010Sep 16, 2015Intellikine, LLCAdenine derivative as pi3k inhibitorEP2933252A1Jul 12, 2010Oct 21, 2015Gilead Sciences, Inc.Apoptosis signal-regulating kinase inhibitorsEP2952583A1Mar 11, 2008Dec 9, 2015Oncolytics Biotech Inc.Reoviruses having modified sequencesEP2966067A1Jun 29, 2012Jan 13, 2016Gilead Sciences, Inc.Oxazepines as ion channel modulatorsEP2977375A1Jul 25, 2014Jan 27, 2016Bayer Pharma AktiengesellschaftAmino-substituted isoxazolesEP2977376A1Jul 25, 2014Jan 27, 2016Bayer Pharma AktiengesellschaftAmino-substituted isoxazolesEP2977377A1Jul 25, 2014Jan 27, 2016Bayer Pharma AktiengesellschaftAmino-substituted isoxazolesEP2993170A1Jun 29, 2012Mar 9, 2016Gilead Sciences, Inc.N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addictionEP3009436A1Jul 8, 2009Apr 20, 2016Intellikine, LLCKinase inhibitors and methods of useEP3075722A1Oct 8, 2009Oct 5, 2016Xgene Pharmaceutical IncGaba conjugates and methods of use thereofEP3085694A1Jun 29, 2012Oct 26, 2016Gilead Sciences, Inc.Fused benzoxazepinones as ion channel modulatorsEP3085696A1Jun 29, 2012Oct 26, 2016Gilead Sciences, Inc.Fused benzoxazepinones as ion channel modulatorsEP3088395A1Jun 29, 2012Nov 2, 2016Gilead Sciences, Inc.Fused benzoxazepinones as ion channel modulatorsWO1995026718A1 *Mar 30, 1995Oct 12, 1995Apollon, Inc.Compositions and methods for delivery of genetic materialWO2001060325A1 *Feb 16, 2001Aug 23, 2001Bentley Pharmaceuticals, Inc.Pharmaceutical compositionWO2002083084A1 *Apr 10, 2002Oct 24, 2002Watson Pharmaceuticals, Inc.Nail compositions and methods of administering sameWO2003000158A1 *Jun 24, 2002Jan 3, 2003Bentley Pharmaceuticals, Inc.Pharmaceutical compositionWO2003024472A2Aug 30, 2002Mar 27, 2003Stem Cell Therapeutics Inc.Prolactin induced increase in neutral stem cell numbers and therapeutical use thereofWO2003042214A2Nov 8, 2002May 22, 2003Cv Therapeutics, Inc.A2b adenosine receptor antagonistsWO2003099231A2May 27, 2003Dec 4, 2003Elan Pharmaceuticals, Inc.Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrinsWO2003099281A2May 21, 2003Dec 4, 2003Cv Therapeutics, Inc.Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetesWO2004069818A1Jan 16, 2004Aug 19, 2004Cv Therapeutics Inc.Substituted heterocyclic compounds useful in the treatment of cardiovascular diseasesWO2004094380A1Apr 14, 2004Nov 4, 2004Eli Lilly And Company(piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonistsWO2005077404A1Feb 14, 2005Aug 25, 2005Stem Cell Therapeutics Corp.Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesisWO2006042414A1Oct 21, 2005Apr 27, 2006Oncolytics Biotech Inc.Improved viral purification methodsWO2006062898A2Dec 6, 2005Jun 15, 2006Siga Technologies, Inc.Compounds and methods for treating hemorrhagic fever virusesWO2006125119A1May 17, 2006Nov 23, 2006Sarcode CorporationCompositions and methods for treatment of eye disordersWO2007028083A2Sep 1, 2006Mar 8, 2007Eli Lilly And Company6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonistsWO2007041270A1Sep 28, 2006Apr 12, 2007Elan Pharmaceuticals, Inc.Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4WO2007041324A1Sep 28, 2006Apr 12, 2007Elan Pharmaceuticals, Inc.Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4WO2007051830A2 *Nov 3, 2006May 10, 2007Laboratorios Belmac, S.A.Composition for the transdermal administration of physiologically active agentsWO2007051830A3 *Nov 3, 2006Oct 11, 2007Belmac S A LabComposition for the transdermal administration of physiologically active agentsWO2007053574A2Oct 31, 2006May 10, 2007Bayer Pharmaceuticals CorporationCombinations comprising sorafenib and interferon for the treatment of cancerWO2007064931A2Dec 1, 2006Jun 7, 2007Bayer Healthcare LlcSubstituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisWO2007093036A1Feb 9, 2007Aug 23, 2007Oncolytics Biotech Inc.Use of local immune suppression to enhance oncolytic viral therapyWO2007101165A1Feb 26, 2007Sep 7, 2007Elan Pharmaceuticals, Inc.Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4WO2008014497A2Jul 27, 2007Jan 31, 2008Cv Therapeutics, Inc.Aldh-2 inhibitors in the treatment of addictionWO2008037484A2 *Sep 27, 2007Apr 3, 2008Paolo BottiFormulations comprising cyclic compoundsWO2008037484A3 *Sep 27, 2007Dec 18, 2008Paolo BottiFormulations comprising cyclic compoundsWO2008045250A1 *Oct 2, 2007Apr 17, 2008Merck & Co., Inc.Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's diseaseWO2008079972A2Dec 20, 2007Jul 3, 2008Bayer Healthcare Llc4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancerWO2008091588A1Jan 22, 2008Jul 31, 2008Targacept, Inc.Intranasal, buccal, and sublingual administration of metanicotine analogsWO2008109026A1 *Mar 3, 2008Sep 12, 2008Mt Cook PharmaPharmaceutical compositions for the localized treatment of neurogenic dysfunctionWO2009006591A1Jul 3, 2008Jan 8, 2009Children's Hospital & Research Center At OaklandInhibitors of polysialic acid de-n-acetylase and methods for using the sameWO2009042543A1Sep 22, 2008Apr 2, 2009Bayer Healthcare LlcPyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinaseWO2009054914A1Oct 17, 2008Apr 30, 2009Sarcode CorporationCompositions and methods for treatment of diabetic retinopathyWO2009114870A2Mar 16, 2009Sep 17, 2009Intellikine, Inc.Kinase inhibitors and methods of useWO2010035261A2Sep 24, 2009Apr 1, 2010Ben Gurion University Of The Negev Research And Development AuthorityAmyloid beta-peptides and methods of use thereofWO2010042759A2Oct 8, 2009Apr 15, 2010Kyphia Pharmaceuticals IncGaba conjugates and methods of use thereofWO2010047737A2Sep 1, 2009Apr 29, 2010Micurx Pharmaceuticals, Inc.Antimicrobial indoline compounds for treatment of bacterial infectionsWO2010051933A2Oct 28, 2009May 14, 2010Bayer Schering Pharma AktiengesellschaftSubstituted sulphonamido phenoxybenzamidesWO2010056527A2Oct 28, 2009May 20, 2010Gilead Palo Alto, Inc.Fused heterocyclic compounds as ion channel modulatorsWO2010074807A1Oct 28, 2009Jul 1, 2010Gilead Palo Alto, Inc.3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulatorsWO2010075266A2Dec 21, 2009Jul 1, 2010Serenity Pharmaceuticals CorporationSafe desmopressin administrationWO2011008709A1Jul 12, 2010Jan 20, 2011Gilead Sciences, Inc.Apoptosis signal-regulating kinase inhibitorsWO2011014462A1Jul 26, 2010Feb 3, 2011Gilead Palo Alto, Inc.Fused heterocyclic compounds as ion channel modulatorsWO2011019752A2Aug 10, 2010Feb 17, 2011Gilead Palo Alto, Inc.A1 adenosine receptor agonist polymorphsWO2011026579A1Aug 24, 2010Mar 10, 2011Bayer Schering Pharma AktiengesellschaftSubstituted aminoquinoxalines as tyrosine threonine kinase inhibitorsWO2011047788A1Oct 7, 2010Apr 28, 2011Bayer Schering Pharma AktiengesellschaftSubstituted benzosulphonamidesWO2011047795A1Oct 12, 2010Apr 28, 2011Bayer Schering Pharma AktiengesellschaftSubstituted benzosulphonamidesWO2011047796A1Oct 12, 2010Apr 28, 2011Bayer Schering Pharma AktiengesellschaftSubstituted halophenoxybenzamide derivativesWO2011056985A2Nov 4, 2010May 12, 2011Gilead Sciences, Inc.Substituted heterocyclic compoundsWO2011063907A1Nov 17, 2010Jun 3, 2011Bayer Schering Pharma AktiengesellschaftSubstituted triazolopyridinesWO2011063908A1Nov 17, 2010Jun 3, 2011Bayer Schering Pharma AktiengesellschaftTriazolopyridinesWO2011064328A1Nov 26, 2010Jun 3, 2011Bayer Schering Pharma AktiengesellschaftTriazolopyridine derivativesWO2011112995A1Mar 11, 2011Sep 15, 2011Gilead Sciences, Inc.Imidazopyridines syk inhibitorsWO2011113862A1Mar 16, 2011Sep 22, 2011Bayer Pharma AktiengesellschaftImidazopyrazinesWO2011123654A1Mar 31, 2011Oct 6, 2011Colucid Pharmaceuticals, Inc.Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonistsWO2011128381A1Apr 13, 2011Oct 20, 2011Novartis AgTriazole compounds as ksp inhibitorsWO2011128388A2Apr 13, 2011Oct 20, 2011Novartis AgOxazole and thiazole compounds as ksp inhibitorsWO2011128407A2Apr 14, 2011Oct 20, 2011Bayer Pharma AktiengesellschaftSubstituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinationsWO2011130728A1Apr 18, 2011Oct 20, 2011Bayer Healthcare LlcSynthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditionsWO2011151259A1May 27, 2011Dec 8, 2011Bayer Pharma AktiengesellschaftSubstituted imidazopyrazinesWO2011157688A1Jun 14, 2011Dec 22, 2011Bayer Pharma AktiengesellschaftSubstituted triazolopyridinesWO2012003220A1Jun 29, 2011Jan 5, 2012Gilead Sciences, Inc.Use of a2b adenosine receptor antagonists for treating pulmonary hypertensionWO2012003387A1Jun 30, 2011Jan 5, 2012Gilead Sciences, Inc.Apoptosis signal-regulating kinase inhibitorsWO2012003392A1Jun 30, 2011Jan 5, 2012Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsWO2012033952A1Sep 8, 2011Mar 15, 2012Micurx Pharmaceuticals, Inc.3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infectionsWO2012041987A1Sep 29, 2011Apr 5, 2012Bayer Pharma AktiengesellschaftSubstituted n-(2-arylamino)aryl sulfonamide-containing combinationsWO2012055953A1Oct 27, 2011May 3, 2012Bayer Pharma AktiengesellschaftSubstituted phenoxypyridinesWO2012062743A1Nov 8, 2011May 18, 2012Bayer Pharma AktiengesellschaftArylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolinesWO2012062745A1Nov 8, 2011May 18, 2012Bayer Pharma AktiengesellschaftAlkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolinesWO2012062748A1Nov 8, 2011May 18, 2012Bayer Pharma AktiengesellschaftAminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesisWO2012075376A2Dec 2, 2011Jun 7, 2012Oncolytics Biotech Inc.Lyophilized viral formulationsWO2012080228A1Dec 13, 2011Jun 21, 2012Bayer Pharma Aktiengesellschaft6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersWO2012080229A1Dec 13, 2011Jun 21, 2012Bayer Pharma AktiengesellschaftImidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disordersWO2012080230A1Dec 13, 2011Jun 21, 2012Bayer Pharma Aktiengesellschaft6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersWO2012080232A1Dec 13, 2011Jun 21, 2012Bayer Pharma Aktiengesellschaft2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersWO2012080234A1Dec 13, 2011Jun 21, 2012Bayer Pharma AktiengesellschaftSubstituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersWO2012080236A1Dec 13, 2011Jun 21, 2012Bayer Pharma Aktiengesellschaft6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disordersWO2012097000A1Jan 10, 2012Jul 19, 2012Pingda RenProcesses for preparing isoquinolinones and solid forms of isoquinolinonesWO2012116237A2Feb 23, 2012Aug 30, 2012Intellikine, LlcHeterocyclic compounds and uses thereofWO2012119007A1Mar 1, 2012Sep 7, 2012N21 Acquisition Holding, LlcCompositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disordersWO2012119949A1Mar 2, 2012Sep 13, 2012Vib VzwMeans and methods for the treatment of neurodegenerative disordersWO2012123419A1Mar 12, 2012Sep 20, 2012Katholieke Universiteit Leuven, K.U.Leuven R&DMolecules and methods for inhibition and detection of proteinsWO2012130905A1Mar 28, 2012Oct 4, 2012Bayer Pharma AktiengesellschaftSubstituted benzimidazolesWO2012131109A2Apr 2, 2012Oct 4, 2012Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V.Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disordersWO2012136531A1Mar 28, 2012Oct 11, 2012Bayer Pharma AktiengesellschaftSubstituted imidazopyridines and intermediates thereofWO2012136549A1Mar 29, 2012Oct 11, 2012Bayer Pharma AktiengesellschaftUse of substituted 2,3-dihydroimidazo[1,2-c]quinazolinesWO2012136553A1Mar 29, 2012Oct 11, 2012Bayer Pharma AktiengesellschaftSubstituted 2,3-dihydroimidazo[1,2-c]quinazoline saltsWO2012143329A1Apr 16, 2012Oct 26, 2012Bayer Intellectual Property GmbhTriazolopyridinesWO2012154340A1Apr 5, 2012Nov 15, 2012Gilead Sciences, Inc.Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patientsWO2012154760A1May 8, 2012Nov 15, 2012Gilead Sciences, Inc.Fused heterocyclic compounds as sodium channel modulatorsWO2012156367A1May 14, 2012Nov 22, 2012Bayer Intellectual Property GmbhAmino-substituted imidazopyridazines as mknk1 kinase inhibitorsWO2012160029A1May 21, 2012Nov 29, 2012Bayer Intellectual Property GmbhSubstituted triazolopyridinesWO2012163942A1May 30, 2012Dec 6, 2012Bayer Intellectual Property GmbhSubstituted aminoimidazopyridazinesWO2012175591A1Jun 21, 2012Dec 27, 2012Bayer Intellectual Property GmbhHeterocyclyl aminoimidazopyridazinesWO2013006400A1Jun 29, 2012Jan 10, 2013Gilead Sciences, Inc.Compounds for the treatment of addictionWO2013006463A1Jun 29, 2012Jan 10, 2013Gilead Sciences, Inc.Oxazepines as ion channel modulatorsWO2013006485A1Jun 29, 2012Jan 10, 2013Gilead Sciences, Inc.Fused benzoxazepinones as ion channel modulatorsWO2013007766A1Jul 12, 2012Jan 17, 2013Vib VzwMeans and methods for the treatment of pathological angiogenesisWO2013012915A1Jul 18, 2012Jan 24, 2013Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereofWO2013012918A1Jul 18, 2012Jan 24, 2013Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereofWO2013032591A1Jul 18, 2012Mar 7, 2013Infinity Pharmaceuticals Inc.Heterocyclic compounds and uses thereofWO2013033377A1Aug 30, 2012Mar 7, 2013Gilead Sciences, Inc.Aldh-2 inhibitors in the treatment of addictionWO2013034570A1Sep 5, 2012Mar 14, 2013Bayer Intellectual Property GmbhAmino-substituted imidazopyridazinesWO2013041634A1Sep 20, 2012Mar 28, 2013Bayer Intellectual Property GmbhSubstituted imidazopyridazinesWO2013043925A1Sep 20, 2012Mar 28, 2013Gilead Sciences, Inc.Sodium channel blockers reduce glucagon secretionWO2013049332A1Sep 27, 2012Apr 4, 2013Infinity Pharmaceuticals, Inc.Inhibitors of monoacylglycerol lipase and methods of their useWO2013087579A1Dec 10, 2012Jun 20, 2013Bayer Intellectual Property GmbhSubstituted triazolopyridines and their use as ttk inhibitorsWO2013087581A1Dec 10, 2012Jun 20, 2013Bayer Intellectual Property GmbhAmino-substituted imidazopyridazinesWO2013093615A1Dec 20, 2012Jun 27, 2013Micurx Pharmaceuticals, Inc.Tricyclic boron compounds for antimicrobial therapyWO2013135612A1Mar 11, 2013Sep 19, 2013Bayer Intellectual Property GmbhSubstituted imidazopyridazinesWO2013144119A1Mar 26, 2013Oct 3, 2013Vib VzwPotent synergistic effect of doxycycline with fluconazole against candida albicansWO2013144189A1Mar 27, 2013Oct 3, 2013Bayer Intellectual Property GmbhAmino-substituted imidazopyridazinesWO2013149909A1Mar 27, 2013Oct 10, 2013Bayer Pharma AktiengesellschaftAmino-substituted imidazopyridazinesWO2013154878A1Apr 3, 2013Oct 17, 2013Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereofWO2013174735A1May 17, 2013Nov 28, 2013Bayer Pharma AktiengesellschaftSubstituted benzothienopyrimidinesWO2013174743A1May 17, 2013Nov 28, 2013Bayer Pharma AktiengesellschaftSubstituted pyrrolopyrimidinesWO2013174744A1May 17, 2013Nov 28, 2013Bayer Pharma AktiengesellschaftThienopyrimidinesWO2013182612A1Jun 5, 2013Dec 12, 2013Bayer Pharma AktiengesellschaftGlucose transport inhibitorsWO2013184698A1Jun 4, 2013Dec 12, 2013Gilead Sciences, Inc.Solid forms of an antiviral compoundWO2013192097A1Jun 17, 2013Dec 27, 2013Intercept Pharmaceuticals, Inc.Preparation, uses and solid forms of obeticholic acidWO2014020041A1Jul 30, 2013Feb 6, 2014Bayer Pharma AktiengesellschaftCombinations for the treatment of cancerWO2014020043A1Jul 30, 2013Feb 6, 2014Bayer Pharma AktiengesellschaftCombinations for the treatment of cancerWO2014028343A1Aug 9, 2013Feb 20, 2014Gilead Sciences, Inc.Solid forms of an antiviral compoundWO2014048869A1Sep 23, 2013Apr 3, 2014Bayer Pharma AktiengesellschaftSubstituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseasesWO2014048894A1Sep 24, 2013Apr 3, 2014Bayer Pharma AktiengesellschaftSubstituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disordersWO2014055960A1Oct 4, 2013Apr 10, 2014Genelux CorporationEnergy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymesWO2014071105A1Nov 1, 2013May 8, 2014Infinity Pharmaceuticals, Inc.Treatment of rheumatoid arthritis and asthma using p13 kinase inhibitorsWO2014071109A1Nov 1, 2013May 8, 2014Infinity Pharmaceuticals, Inc.Treatment of cancers using pi3 kinase isoform modulatorsWO2014100541A1Dec 20, 2013Jun 26, 2014Gilead Sciences, Inc.Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitorsWO2014118135A1Jan 28, 2014Aug 7, 2014Bayer Pharma AktiengesellschaftAmidoimidazopyridazines as mknk-1 kinase inhibitorsWO2014118186A1Jan 28, 2014Aug 7, 2014Bayer Pharma AktiengesellschaftAmino-substituted isothiazolesWO2014118226A1Jan 29, 2014Aug 7, 2014Bayer Pharma AktiengesellschaftSubstituted pyrazolopyrimidinylamino-indazolesWO2014118229A1Jan 29, 2014Aug 7, 2014Bayer Pharma AktiengesellschaftSubstituted thienopyrimidines and pharmaceutical use thereofWO2014151386A1Mar 13, 2014Sep 25, 2014Infinity Pharmaceuticals, Inc.Salts and solid forms of isoquinolinones and composition comprising and methods of using the sameWO2014160873A1Mar 27, 2014Oct 2, 2014Gilead Sciences, Inc.Benzimidazolone derivatives as bromodomain inhibitorsWO2014166820A1Apr 4, 2014Oct 16, 2014Bayer Pharma AktiengesllschaftUse of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomasWO2014182929A1May 8, 2014Nov 13, 2014Gilead Sciences, Inc.Benzimidazole derivatives as bromodomain inhibitorsWO2015017610A1Jul 31, 2014Feb 5, 2015Gilead Sciences, Inc.Syk inhibitorsWO2015051241A1Oct 3, 2014Apr 9, 2015Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereofWO2015051244A1Oct 3, 2014Apr 9, 2015Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereofWO2015061204A1Oct 20, 2014Apr 30, 2015Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereofWO2015080707A1Nov 26, 2013Jun 4, 2015Gilead Sciences, Inc.Quinoline derivatives as bromodomain inhibitorsWO2015082376A2Dec 1, 2014Jun 11, 2015Bayer Pharma AktiengesellschaftUse of pi3k-inhibitorsWO2015083008A1Dec 5, 2014Jun 11, 2015Acerta Pharma B.V.Therapeutic combination of a pi3k inhibitor and a btk inhibitorWO2015084992A1Dec 3, 2014Jun 11, 2015Gilead Sciences, Inc.Methods for treating cancersWO2015095370A1Dec 17, 2014Jun 25, 2015Gilead Sciences, Inc.Fused heterocyclic compounds as ion channel modulatorsWO2015100144A1Dec 18, 2014Jul 2, 2015Gilead Sciences, Inc.Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptideWO2015104254A1Jan 6, 2015Jul 16, 2015Bayer Pharma AktiengesellschaftAmido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disordersWO2015110923A2Jan 21, 2015Jul 30, 2015Acerta Pharma B.V.Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitorWO2015123434A1Feb 12, 2015Aug 20, 2015Gilead Sciences, Inc.Solid forms of an ion channel modulatorWO2015143012A1Mar 18, 2015Sep 24, 2015Infinity Pharmaceuticals, Inc.Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disordersWO2015168079A1Apr 28, 2015Nov 5, 2015Infinity Pharmaceuticals, Inc.Pyrimidine or pyridine derivatives useful as pi3k inhibitorsWO2015181633A2Apr 10, 2015Dec 3, 2015Acerta Pharma B.V.Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinaseWO2015185998A2Apr 10, 2015Dec 10, 2015Acerta Pharma B.V.Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinaseWO2015187684A1Jun 2, 2015Dec 10, 2015Gilead Sciences, Inc.Tank-binding kinase inhibitor compoundsWO2015191726A1Jun 10, 2015Dec 17, 2015Gilead Sciences, Inc.Phosphatidylinositol 3-kinase inhibitorsWO2015191754A2Jun 10, 2015Dec 17, 2015Gilead Sciences, Inc.Phosphatidylinositol 3-kinase inhibitorsWO2016010862A1Jul 10, 2015Jan 21, 2016Gilead Sciences, Inc.Combinations for treating cancersWO2016024227A1Aug 11, 2015Feb 18, 2016Acerta Pharma B.V.Btk inhibitors to treat solid tumors through modulation of the tumor microenvironmentWO2016054491A1Oct 2, 2015Apr 7, 2016Infinity Pharmaceuticals, Inc.Heterocyclic compounds and uses thereofWO2016055982A1Oct 9, 2015Apr 14, 2016Acerta Pharma B.V.Quinoline and quinazoline compoundsWO2016065028A1Oct 21, 2015Apr 28, 2016Ariad Pharmaceuticals, Inc.Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamineWO2016081772A1Nov 19, 2015May 26, 2016Allergan, Inc.Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonistWO2016087994A1Nov 24, 2015Jun 9, 2016Acerta Pharma B.V.Btk inhibitors to treat solid tumors through modulation of the tumor microenvironmentWO2016105453A1Dec 22, 2015Jun 30, 2016Gilead Sciences, Inc.Solid forms of an ask1 inhibitorWO2016116777A1Jun 17, 2015Jul 28, 2016Acerta Pharma B.V.Compositions and methods for treatment of chronic lymphocytic leukemia and small lymphocytic leukemia using a btk inhibitorWO2016131794A1Feb 16, 2016Aug 25, 2016Bayer Pharma Aktiengesellschaft3-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathwayWO2016131808A1Feb 16, 2016Aug 25, 2016Bayer Pharma Aktiengesellschaft1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathwayWO2016131810A1Feb 16, 2016Aug 25, 2016Bayer Pharma AktiengesellschaftN-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathwaysWO2016149271A1Mar 15, 2016Sep 22, 20163-V Biosciences, Inc.Heterocyclic modulators of lipid synthesisWO2016166186A1Apr 14, 2016Oct 20, 2016Bayer Pharma AktiengesellschaftNovel aryl-cyanoguanidine compounds* Cited by examinerClassifications U.S. Classification514/183, 514/450, 514/431International ClassificationA61K9/70, A61K47/22, A61K47/08, A61K9/00Cooperative ClassificationA61K9/0014, A61K47/08, A61K9/7069, A61K47/22European ClassificationA61K47/08, A61K47/22, A61K9/00M3, A61K9/70E2B6DLegal EventsDateCodeEventDescriptionMar 4, 1991ASAssignmentOwner name: CONREX PHARMACEUTICAL CORPORATION, MALVERN, PA A CFree format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:HSIEH, DEAN;REEL/FRAME:005617/0338Effective date: 19910215Jan 17, 1995REMIMaintenance fee reminder mailedJun 12, 1995FPAYFee paymentYear of fee payment: 4Jun 12, 1995SULPSurcharge for late paymentAug 22, 1995FPExpired due to failure to pay maintenance feeEffective date: 19950614May 23, 1997ASAssignmentOwner name: HSU, YUNGTAI A., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONREX PHARMACEUTICAL CORPORATION;REEL/FRAME:008535/0134Effective date: 19970501Jan 5, 1999REMIMaintenance fee reminder mailedFeb 11, 1999ASAssignmentOwner name: CONREX PHARMACEUTICAL CORP., PENNSYLVANIAFree format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:HSU, YUNGTAI;REEL/FRAME:009756/0749Effective date: 19990210Feb 22, 1999ASAssignmentOwner name: BENTLEY PHARMACEUTICALS, INC., FLORIDAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONREX PHARMACEUTICAL CORPORATION;REEL/FRAME:009773/0825Effective date: 19990211Mar 31, 1999FPAYFee paymentYear of fee payment: 8Mar 31, 1999SULPSurcharge for late paymentAug 9, 2002FPAYFee paymentYear of fee payment: 12Aug 11, 2008ASAssignmentOwner name: CPEX PHARMACEUTICALS, INC., NEW HAMPSHIREFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENTLEY PHARMACEUTICALS, INC.;REEL/FRAME:021354/0941Effective date: 20080630RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services